Poster Presentations

* Presenting Author

PP-WE-001 PLATELET ACTIVATION AND THROMBOSIS BY ANTI-CD40L IMMUNE COMPLEXES
L. Robles, A. Amirkhosravi* (US), T. Meyer, H. Desai, M. Davila, F. Langer, M. Amaya, J. Francis

PP-WE-002 RETICULATED PLATELETS AND PLATELET REACTIVITY IN RENAL TRASPLANT RECIPIENTS ON ANTIPLATELET THERAPY
F. Cesari* (IT), R. Marcucci, A. Gori, F. Sofi, R. Caporale, R. Paniccia, E. Antonucci, M. Salvadori, G. Gensini, R. Abbate, M. Zanazzi

PP-WE-003 PLATELET AGGREGABILITY IS MODULATED BY ENOS LOCUS IN NON-TYPE 2 DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME
C. Fatini, E. Sticchi, F. Sofi* (IT), P. Bolli, R. Marcucci, B. Giusti, R. Paniccia, A. Gori, G. Gensini, R. Abbate

PP-WE-004 DIRECT INTERACTION BETWEEN GALPHA13 AND INTEGRIN BETA3 SUBUNIT MEDIATES INTEGRIN OUTSIDE-IN SIGNALLING
H. Gong* (US), P. Flevaris, C. Chow, S. Lam, T. Voyno-Yasenetskaya, T. Kozasa, X. Du

PP-WE-005 ARE PLATELETS PHAGOCYTES OR COVERCYTES? AN ULTRASTRUCTURAL STUDY OF INTERACTION BETWEEN PORPHYROMONAS GINGIVALIS, AN ORAL BACTERIUM AND HUMAN PLATELETS
H. Suzuki* (JP), X. Li, H. Nakamura, Y. Inoue, Y. Chen, M. Umeda, T. Iwai

PP-WE-006 RHO GTPASES RAC1 AND RHOA DIFFERENTIALLY REGULATE PLATELET ACTIN REORGANIZATION, SECRETION AND AGGREGATION
H. Akbar* (US), K. Funk, R. Perveen, X. Shang, Y. Zheng

PP-WE-007 THE ROLE AND REGULATION OF MTOR IN HUMAN PLATELETS
R. W. Hunter, I. Hers* (UK)

PP-WE-008 RAPID PROCOAGULANT PHOSPHATIDYLSERINE EXPOSURE RELIES ON HIGH CYTOSOLIC CALCIUM RATHER THAN ON MITOCHONDRIAL DEPOLARIZATION
A. Arachiche, D. Kerbiriou-Nabias, I. Garcin, T. Letellier, J. Dachary-Prigent* (FR)

PP-WE-009 INFLUENCE OF CORNARY STENT IMPLANTATION ON PLATELET ACTIVATION
J. Gu* (CN), X. Gu, H. Gu, L. Wang

PP-WE-010 POST-ACTIVATION SIGNALING BY ALPHAIIBBETA3 NECESSITATES PDI-MEDIATED DISULFIDE EXCHANGE
O. Romanenko, V. Sheptovitsky, R. Mor Cohen, N. Rosenberg, J. Lahav* (IL)

PP-WE-011 INTEGRIN3 MEMBRANE-PROXIMAL AND -DISTAL RESIDUES COOPERATIVELY REGULATE TALIN-MEDIATED IIB3 ACTIVATION
J. Yamanouchi* (JP), T. Hato, H. Fujiwara, Y. Yakushijin, M. Yasukawa

PP-WE-012 REGULATION OF PLATELET THROMBOXANE GENERATION DOWNSTREAM OF G12/13 PATHWAYS THROUGH FOCAL ADHESION KINASE
K. Bhavaraju* (US), P. Lakhani, R. Dorsam, J. Jin, A. Sanjay, S. Kunapuli

PP-WE-013 THE NOVEL S527F MUTATION IN THE INTEGRIN BETA3 CHAIN INDUCES A HIGH AFFINITY (ALPHA)IIB(BETA)3 RECEPTOR BY HINDERING ADOPTION OF THE BENT CONFORMATION
K. Vanhoorelbeke* (BE), S. F. de Meyer, I. Pareyn, C. Melchior, S. Plançon, C. Margue, O. Pradier, P. Fondu, N. Kieffer, T. A. Springer, H. Deckmyn

PP-WE-014 PLATELET THROMBIN RECEPTORS PAR1 AND PAR4 ACT IN A SYNERGISTIC MANNER
K. V. Öberg* (SE), S. Kulsum, N. Boknäs, S. Ramström, T. L. Lindahl

PP-WE-015 AN INHIBITORY ROLE OF PLATELET CD109 IN PLATELET FUNCTION
K. Matsumoto* (JP), Y. Matsubara, H. Hoshino, K. Yokoyama, G. Watanabe, T. Shibano, N. Suzuki, Y. Ikeda, M. Murata

PP-WE-016 CALDAG-GEFI: AT THE NEXUS OF CALCIUM-DEPENDENT PLATELET ACTIVATION
L. Stefanini* (US), R. C. Roden, W. Bergmeier

PP-WE-017 EVALUATION OF DIFFERENT BLOOD DRAWING TECHNIQUES ON THE RESULTS OF PLATELET FUNCTION TESTS
M. D. Lance* (NL), Y. M. C. Henskens, H. M. S. Theunissen, R. van Oerle, K. Hamulyak, H. ten Cate, M. A. E. Marcus

PP-WE-018 COOPERATIVE CALCIUM SIGNALING ELICITED BY GLICOPROTEINS (GP)IB-IX-V, GPVI AND INTEGRIN ALPHA2BETA1 DURING PLATELET ADHESION TO COLLAGEN UNDER FLOW
M. R. Cozzi, M. Battiston, M. Mazzucato, M. Jandrot Perrus, Z. M. Ruggeri, L. de Marco* (IT)

PP-WE-019 A ROLE FOR SHIP1 IN PLATELET INTERNAL CONTRACTION VIA THE CONTROL OF ACTOMYOSIN AND MICROTUBULE DYNAMICS
M. Gratacap* (FR), S. Severin, G. Chicanne, V. Martin, S. Allart, A. Eckly, M. Plantavid, B. Payrastre

PP-WE-020 PKC ALPHA REGULATES GPVI-DEPENDENT CALCIUM SIGNALLING AND PHOSPHATIDYLSERINE EXPOSURE IN PLATELETS
M. T. Harper* (UK), A. W. Poole

PP-WE-021 PRE-OPERATIVE PLATELET CD40 LIGAND EXPRESSION PREDICTS ADVERSE CARDIAC EVENTS AFTER ORTHOPAEDIC SURGERY
M. J. Ray* (AU), D. Walters, S. Crawford, D. Enever, L. Calabro, T. Sirisena, R. Crawford

PP-WE-022 EFFECTS OF THE 5-HT4 RECEPTOR AGONIST, TEGASEROD, ON IN VITRO HUMAN PLATELET AGGREGATION
V. L. Serebruany, M. El Mouelhi* (US), H. Pfannkuche, K. Rose, M. Marro, D. J. Angiolillo

PP-WE-023 PROTEIN KINASE A PHOSPHORYLATES MULTIPLE GPIB ALPHA; CYTOPLASMIC RESIDUES: IMPLICATIONS RECEPTOR REGULATION
A. D. Munday* (US), J. A. Lopez

PP-WE-024 TISSUE FACTOR PRE-MRNA SPLICING IN PLATELETS FROM HEALTHY SUBJECTS AND TYPE 2 DIABETES MELLITUS PATIENTS
A. J. Gerrits* (NL), C. A. Koekman, J. W. N. Akkerman

PP-WE-025 USE OF THE PLATELET INDICES FOR DIFFERENTIAL DIAGNOSIS OF PEDIATRIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
H. Nakadate* (JP), M. Kaida, S. Furukawa, M. Ishii, M. Higashihara

PP-WE-026 LEVELS OF VON WILLEBRAND FACTOR AS MEASURE OF ENDOTHELIAL DYSFUNCTION ARE INCREASED IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION
I. Seljeflot* (NO), S. Ulimoen, S. Enger, H. Arnesen, A. Tveit

PP-WE-027 EFFECTS OF ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE POLYMORPHISMS AND PLATELET-DERIVED NITRIC OXIDE ON PLATELET AGGREGATION
J. Kim* (KR), S. Park, E. Park, Y. Koo, J. Kim, I. Kim, S. Yoon, H. Yun-Choi, S. Park

PP-WE-028 MMP-13: A NOVEL PLATELET PROTEIN AND A POTENT INHIBITOR OF PLATELET AGGREGATION
J. Howes* (UK), N. Pugh, R. W. Farndale

PP-WE-029 BOTROCETIN-DEPENDENT BINDING OF VON WILLEBRAND FACTOR TO THE PLATELET RECEPTOR GLYCOPROTEIN IB ALPHA CHAIN IS ENHANCED BY THE CENTRAL MACROGLYCOPEPTIDE REGION OF THE RECEPTOR
T. K. Biswas, J. L. Miller* (US)

PP-WE-030 DIMINISHED SYK PHOSPHORYLATION IN PLATELETS UNDERLIES IMPAIRED THROMBUS GROWTH IN RESPONSE TO COLLAGEN IN MICE LACKING SEMAPHORIN 4D
K. M. Wannemacher* (US), L. Zhu, H. Jiang, K. Fong, T. J. Stalker, D. Lee, A. Tran, K. Neeves, S. Maloney, A. Kumanogoh, D. Hammer, S. L. Diamond, L. F. Brass

PP-WE-031 EFFECT OF ASPIRIN ADMINISTRATION ON GPIB ALPHA SHEDDING: ASSOCIATION OF GLYCOCALICIN LEVEL WITH PLATELET SENSITIVITY TO ASPIRIN
K. Yamaji* (JP), Y. Matsubara, H. Hoshino, N. Suzuki, Y. Ikeda, M. Murata

PP-WE-032 SRC AND PI3-KINASE TRANSMIT SIGNALS LEADING TO CK2 ACTIVATION IN PAR1AP-STIMULATED PLATELETS
K. Nakanishi* (JP), M. Ido, Y. Komada, T. Hayashi, K. Suzuki

PP-WE-033 MODULATION OF PLATELET REACTIVITY TO THROMBIN BY FLAVONOIDS: INTERFERENCE ON PAR1 AND PAR4 SIGNALING
L. Navarro-Núñez* (ES), M. Lozano, J. Guerrero, C. Martínez, V. Vicente, J. Castillo, J. Rivera

PP-WE-034 EFFICACY OF MODIFIED C-REACTIVE PROTEIN IN THE MODULATION OF PLATELET FUNCTION UNDER DIFFERENT EXPERIMENTAL CONDITIONS
M. Boncler* (PL), J. Rywaniak, B. Rychlik, C. Watala

PP-WE-035 ROLE OF GALECTIN-8 AS A MODULATOR OF PLATELET ACTIVATION
M. A. Romaniuk* (AR), M. V. Tribulatti, V. Cattaneo, J. Etulain, O. Campetella, M. Schattner

PP-WE-036 STORAGE OF BLOOD COMPONENTS DOES NOT DECREASE THEIR HEMOSTATIOC POTENTIAL: IN VITRO ASSESSMENT OF FRESH VERSUS STORED BLOOD COMPONENTS USING THROMBOELASTOGRAPHY
M. H. Ellis* (IL), G. Bartfeld, A. Lubetzky, V. Yahalom, G. Kenet

PP-WE-037 THROMBOGENIC MUTATIONS IN GLANZMANN’S THROMBASTHENIA PATIENTS
M. Kannan* (IN), B. K. Yadav, F. Ahmad, J. Fareed, R. Saxena

PP-WE-038 TIME COURSE OF ASPIRIN EFFECT ON PLATELET FUNCTION EXAMINED BY BLEEDING TIME, PFA-100 AND WHOLE BLOOD AGGREGOMETRY
K. von Pape, C. Jambor, M. Spannagl* (DE), H. Weisser

PP-WE-039 MULTIPLE ELECTRODE PLATELET AGGREGOMETRY FOR THE EVALUATION OF VON WILLEBRAND DISEASE
S. Lison, A. Dick, A. Giebl, T. Kauke, A. Perchuc, M. Spannagl* (DE)

PP-WE-040 PPAR-GAMMA AGONISTS 15D-PGJ2, ROSIGLITAZONE AND CIGLITAZONE ENGAGE IN NON-GENOMIC SIGNALLING PATHWAYS THAT INHIBIT HUMAN PLATELET FUNCTION IN PPAR-GAMMA -DEPENDENT MECHANISMS
M. Spyridon* (UK), L. A. Moraes, W. J. Kaiser, C. I. Jones, J. M. Gibbins

PP-WE-041 PROTEOMICS OF PLATELET SECRETOME IN PATIENTS WITH DELTA STORAGE POOL DISEASE
M. di Michele* (BE), C. Thys, W. D’Hertog, E. Waelkens, R. de Vos, K. Peerlinck, C. van Geet, K. Freson

PP-WE-042 EXTRACELLULAR ACIDOSIS PROMOTES PLATELET-MEDIATED INFLAMMATORY RESPONSES
M. Schattner* (AR), M. A. Romaniuk, J. Etulain, L. P. D´atri, E. Malaver, S. Negrotto, R. Pozner

PP-WE-043 DARK CHOCOLATE EFFECT ON PLATELET ACTIVITY, C-REACTIVE PROTEIN AND LIPID PROFILE:A PILOT STUDY
M. Hamed* (US), S. Gambert, K. Bliden, O. Bailon, A. Singla, M. Antonino, F. Hamed, U. Tantry, P. A. Gurbel

PP-WE-044 SHEAR INDUCED PLATELET ADHESION STIMULATES CORTACTIN TYROSINE PHOSPHORYLATION
N. Savion* (IL), I. Budnik, B. Shenkman

PP-WE-045 DETECTION OF P2Y14 RECEPTOR PROTEIN ON PLATELETS AND INVESTIGATION OF THE ROLE OF P2Y14 IN PLATELET FUNCTION
N. Dovlatova* (UK), Y. D. Wijeyeratne, S. C. Fox, P. Manolopoulos, A. J. Johnson, A. E. White, L. Latif, V. Ralevic, S. Heptinstall

PP-WE-046 CONVERTION OF LYMPHOCYTES CHROMATINE AND NEUTROPHILES UNDER CONDITIONS OF THE HEAT SHOCK IN VITRO: POSSIBLE CONNECTION WITH PLATELETS MORPHOLOGY
N. G. Kruchynsky* (BY), S. Vishnevskaya

PP-WE-047 FINE MAPPING THE VWF A1 DOMAIN BY PHAGE DISPLAY
A. Yee* (US), F. Tan, D. Ginsburg

PP-WE-048 PLATELET ACTIVATION AND PLATELET-LEUKOCYTE MIXED CONJUGATES IN PATIENTS WITH ATRIAL FIBRILLATION
S. Alberti, G. Angeloni, C. Tamburrelli, A. Pampuch, B. Izzi, L. Messano, Q. Parisi, M. Santamaria, M. B. Donati, G. de Gaetano, C. Cerletti* (IT)

PP-WE-049 EFFECT OF COATING CONDITIONS ON COLLAGEN MATRIX FORMATION AND TO THE VON WILLEBRAND FACTOR AND PLATELET BINDING TO IT
S. Mendelboum Raviv, K. Szekeres-Csiki, A. Jenei, J. Nagy, B. Shenkman, N. Savion, J. Harsfalvi* (HU)

PP-WE-050 PROTEASE-ACTIVATED RECEPTORS 1 AND 2 ACTIVATION INDUCES TISSUE FACTOR THROUGH MITOCHONDRIAL REACTIVE OXYGEN SPECIES
C. Banfi, M. Brioschi, S. S. Barbieri, S. Eligini, S. Barcella, E. Tremoli, S. Colli, L. Mussoni* (IT)

PP-WE-051 FECL3-INDUCED THROMBUS FORMATION IN THE INFERIOR VENA CAVA OF MICE REQUIRES PLATELETS, GLYCOPROTEIN IB-IX, AND VON WILLEBRAND FACTOR
M. Joglekar* (US), J. Ware, T. K. Gartner

PP-WE-052 INVESTIGATION OF THE EFFECT OF DIFFERENTIAL PLATELET RECEPTOR ENGAGEMENT ON THROMBUS FORMATION USING COLLAGEN PEPTIDES
N. Pugh* (UK), D. G. Bihan, R. W. Farndale

PP-WE-053 CIB1 CONTROLS INTEGRIN ALPHA IIB BETA 3-DEPENDENT PLATELET SPREADING BY REGULATING FAK ACTIVATION
U. P. Naik* (US), M. U. Naik

PP-WE-054 ENHANCED SHEAR-INDUCED ADHESION ACTIVITY AND DECREASED MICROMOBILITY OF PLATELETS RELATED TO THE ALPHA2 807TT VARIANT OF INTEGRIN ALPHA2 BETA1
R. E. Scharf, V. R. Stoldt* (DE)

PP-WE-055 CD40L MODULATES PLATELET THROMBUS FORMATION UNDER ARTERIAL FLOW CONDITIONS
R. E. Scharf, E. Reiff, V. R. Stoldt* (DE)

PP-WE-056 ROLE OF THE D’D3 SUBUNIT OF VON WILLEBRAND FACTOR IN THE SHEAR ENHANCED BINDING OF PLATELETS UNDER FLOW CONDITIONS
R. A. Penkala* (US), A. Tu, A. D. Munday, P. Lenting, H. Deckmyn, J. A. Lopez, W. Thomas

PP-WE-057 CD3 IS EXPRESSED AND SYNTHESIZED BY HUMAN PLATELETS
C. G. Sáez* (CL), V. Matus, O. Panes, J. Pereira, D. Mezzano

PP-WE-058 PLATELETS ABILITY TO PHAGOCYTOSIS DEPENDS ON THEIR FUNCTIONAL ACTIVITY AND GPIIB/IIIA
E. M. Gupalo* (RU), L. L. I. Buryachkovskaya, A. A. B. Sumarokov

PP-WE-059 A NOVEL ANALYSIS OF INITIAL PLATELET-ADHESION IN FLOWING BLOOD
G. R. Meade* (IE), B. Lincoln, A. J. Ricco, N. Kent, L. Basabe-Desmonts, S. O’Brien, L. P. Lee, B. D. MacCraith, D. Kenny

PP-WE-060 NOVEL MOUSE ANTI-MOUSE GPIBALPHA MONOCLONAL ANTIBODIES: DEVELOPMENT AND CHARACTERIZATION OF NEW REAGENTS FOR RESEARCH IN THROMBOSIS AND HEMOSTASIS
G. Zhu* (CA), S. Lang, C. Li, A. Reheman, P. Chen, J. Ware, Z. Ruggeri, J. Freedman, H. Ni

PP-WE-061 HIGH RESOLUTION EM-TOMOGRAPHY OF A VITRIFIED PLATELET
H. E. van Nispen Tot Pannerden, F. de Haas, H. F. G. Heijnen* (NL)

PP-WE-062 THE ROLE OF ANTIPHOSOLIPID AND ANTIPLATELET ANTIBODIES IN PLATELET DYSFUNCTION: COMPUTER-AIDED VISUALIZATION
I. Vasilenko* (RU), I. Kastrikina, V. Metelin, T. Reshetnyak

PP-WE-063 PLATELET CALCIUM AND PHOSPHOINOSITIDE SIGNALING THROUGH COMPUTATIONAL MODELING
J. E. Purvis* (US), M. S. Chatterjee, R. Radhakrishnan, L. F. Brass, S. L. Diamond

PP-WE-064 MULTIPLE ANTIBODY FLOW CYTOMETRY FOR FAST AND EFFICIENT EVALUATION OF PLATELET SURFACE ANTIGENS AND ACTIVATION MARKERS
J. van Velzen* (NL), W. L. van Heerde, J. Boezeman

PP-WE-065 TLT-1 INDUCTION DURING DENGUE FEVER MAY PROMOTE PLATELET ENDOTHELIAL CELL INTERACTION
J. Morales* (PR), K. Vila, J. Gattis, K. Colon, J. Lubkowski, P. Sanabria, R. Hunter, A. Washington

PP-WE-066 FIVE NOVEL MUTATIONS IDENTIFIED IN THE GLICOPROTEINS IBA, IBB AND 9 GENES AMONG 15 UNRELATED PATIENTS WITH BERNARD SOULIER SYNDROME IN BRAZIL
L. H. Siqueira* (BR), A. Santos, M. Perlingeiro Beltrame, V. Oliveira Duarte, E. Vinícius de Paula, J. Maria Annichino-Bizzacchi, M. Castro Ozelo

PP-WE-067 THE ROLE OF CHEMOKINES, GROWTH FACTORS AND ELECTRON MICROSCOPY IN DIAGNOSIS OF DIABETIC NEPHROPATHY
E. A. A. Khaled* (EG), A. H. Hussein, E. A. Waked, S. A. Badr, K. A. Younis

PP-WE-068 PLATELET FUNCTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
J. Maly* (CZ), P. Bradna, Z. Hrncir, T. Soukup, P. Dulicek, M. Pecka, R. Maly

PP-WE-069 RISK FACTORS FOR THROMBOTIC OR HEMORRHAGIC COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA (ET) PATIENTS (PTS)
J. Park* (KR), B. Kim, H. Kim, S. Bang, I. Kim, S. Yoon, D. Lee, J. Lee, S. Park, B. Kim

PP-WE-070 SERIOUS CONGENITAL DEFICIENCY OF FVII AND ACQUIRED ITP - THE RARE COMBINATION OF TWO BLEEDING DISORDERS
J. Slechtova* (CZ), Z. Hajsmanova

PP-WE-071 PLATELET SECRETION CONTRIBUTES TO THE DEVELOPMENT OF ATHEROSCLEROSIS
J. M. Patton* (US), R. A. McNamee, S. M. King, H. Mehta, G. L. Reed

PP-WE-072 A CASE CONTROL STUDY ON PLATELET RESPONSE TO ANTIPLATELET THERAPY IN SURVIVORS OF LATE STENT THROMBOSIS
K. Winckers* (NL), V. Poenitz, R. van Oerle, K. Noordermeer, H. ten Cate, D. W. T. Nilsen

PP-WE-073 EVALUATION OF A NEW KIT FOR QUANTITATION OF PLATELET ASSOCIATED IMMUNOGLOBULINS
L. Le Flem* (FR), F. Ballon, S. Aguilar

PP-WE-074 EVALUATION OF THE INCIDENCE, MATERNAL AND NEONATAL COMPLICATIONS OF THE HELLP SYNDROME AND ITS RISK FACTORS
M. Kashanian* (IR), N. Sohrabi, E. Rafiee Khoshnood

PP-WE-075 PLATELETS AGGREGATION CHANGES IN PATIENTS WITH RENDU OSLER DISEASE – BRIEF REPORT
V. I. Popov* (RO), C. Socoliuc, H. Bumbea, M. Onisai, A. Vladareanu, T. Savopol, E. Kovacs

PP-WE-076 MEGAKARYOCYTE MIGRATION AND THROMBOPOIESIS ARE REGULATED BY SRC KINASES AND PLCGAMMA2, BUT NOT BY THE GPVI-FCRGAMMA-CHAIN
A. Mazharian* (UK), T. S. Dhanjal, Y. Zhao, C. D. Buckley, S. P. Watson

PP-WE-077 DIFFERENTIAL ROLES OF CAMP AND CGMP IN MEGAKARYOCYTE MATURATION AND PLATELET FORMATION
A. Jurak Begonja* (US), S. Gambaryan, H. Schulze, S. Patel Hett, J. E. Italiano, J. H. Hartwig, U. Walter

PP-WE-078 ROLE OF THE HSP40 DNAJC10 IN ALPHAIIB-BETA3 BIOGENESIS
A. Chen, M. Yazdani-Abyaneh, B. Mitchell* (US)

PP-WE-079 DISABLED-2 IS A KEY REGULATOR DURING MESODERMAL DIFFERENTIATION AND MEGAKARYOPOIESIS OF MURINE EMBRYONIC STEM CELLS
C. Huang* (TW), J. Cheng, C. Lin, C. Tseng

PP-WE-080 SYNTHESIS OF PROTEIN S BY HUMAN MEGAKARYOCYTES
C. Radu* (IT), C. Bulato, L. Spiezia, S. Gavasso, G. Tognin, M. Fadin, P. Simioni

PP-WE-081 IN VITRO ADHESION CULTURES OF HUMAN MEGAKARYOCYTES AS A TOOL FOR STUDYING MEGAKARYOCYTIC DEVELOPMENT AND PROPLATELETS FORMATION
C. Radu* (IT), P. Simioni

PP-WE-082 DIRECTED DIFFERENTIATION OF THE MEGAKARYOCYTE LINEAGE FROM HUMAN ES CELLS
D. L. French* (US), M. Jirouskova, B. S. Coller, M. Kennedy, G. Keller

PP-WE-083 MEGAKARYOCYTOPOIESIS IN C-MPL KNOCKOUT NEONATAL VS. ADULT MICE
F. Ferrer-Marin* (US), Z. Hu, Z. Liu, W. Slayton, M. Bailey, R. K. Gutti, M. Sola-Visner

PP-WE-084 HUMAN PLATELETS PRODUCED IN NOD/SCID MICE UPON TRANSPLANTATION OF HUMAN CORD BLOOD CD34+ CELLS ARE FUNCTIONALLY ACTIVE IN AN EX VIVO FLOW MODEL OF THROMBOSIS
I. I. Salles* (BE), T. Thijs, C. Brunaud, S. F. de Meyer, J. Thys, K. Vanhoorelbeke, H. Deckmyn

PP-WE-085 THROMBOPOIETIC EFFECT OF VPAC1 INHIBITION IN MURINE AND HUMAN THROMBOPOIESIS
K. Peeters* (BE), I. I. Salles, M. F. Hoylaerts, H. Deckmyn, C. van Geet, K. Freson

PP-WE-086 PROTEOLYSIS OF ADAMTS13 IN ACUTE PHASE THROMBOTIC THROMBOCYTOPENIC PURPURA
H. B. Feys* (BE), N. Vandeputte, K. Peerlinck, F. Peyvandi, K. Vanhoorelbeke

PP-WE-087 ADAMTS-13 ACTIVITY AND ANTIGEN IN COMMERCIAL VON-WILLEBRAND-FACTOR (VWF) CONCENTRATES
I. Scharrer* (DE), T. Vigh, M. Böhm-Weigert

PP-WE-088 MONOCLONAL ANTI-VON WILLEBRAND FACTOR ANTIBODY-SZ-34 INHIBITS PROTEOLYTIC CLEAVAGE OF VWF BY ADAMTS13 UNDER SHEAR STRESS
J. Zhang* (CN), N. Dong, Z. Ma, C. Ruan

PP-WE-089 SPECTRUM OF ADAMTS13 GENE MUTATIONS IN 19 PATIENTS WITH ADAMTS13 DEFICIENCY
J. C. Calderzzo* (AR), A. C. Kempfer, L. Keller, A. Sánchez Luceros, A. I. Woods, Y. P. Powazniak, M. A. Lazzari

PP-WE-090 PROTECTIVE PROPERTY OF ADAMTS13 IN A MOUSE-MODEL OF ISCHEMIC STROKE
K. Nishio* (JP), M. Fujioka, K. Hayakawa, K. Mishima, M. Fujiwara, F. Banno, K. Kokame, T. Miyata, Y. Shida, M. Sugimoto, T. Ueyama, H. Fukushima, K. Okuchi

PP-WE-091 PLATELET FUNCTION AND THE VON WILLEBRAND FACTOR PROTEOLYSIS BY RADAMS13
L. I. Buryachkovskaya* (RU), N. E. Dovlatova, I. A. Uchitel, A. B. Sumarokov, E. Limonov

PP-WE-092 ADAMTS13 AND VWF ANTIGENS ASSESSMENT IN PATIENTS UNDERGOING HEMODIALYSIS WITH AND WITHOUT THROMBOTIC COMPLICATIONS
D. R. A. Rios, M. G. Carvalho, D. A. Guimarães, A. C. S. Silva, E. M. Lima, R. A. Souza, L. M. S. Dusse* (BR)

PP-WE-093 STUDY OF ADAMTS13 ISOFORMS IN HUVEC
M. A. Carrivale* (AR), V. A. Zapata, L. Keller, A. Sánchez Luceros, A. C. Kempfer, M. A. Lazzari

PP-WE-094 REAL TIME QUANTITATIVE PCR OF ADAMTS 13 IN PLATELETS AND HUMAN ENDOTHELIAL CELLS
M. A. Carrivale* (AR), A. C. Kempfer, Y. P. Powazniak, A. Sánchez Luceros, V. A. Zapata, M. A. Lazzari

PP-WE-095 THE PROTEIN TYROSINE KINASE INHIBITOR DASATINIB INHIBITS P2Y12 AND PAR-1 MEDIATED PLATELET ACTIVATION AND GRANULE RELEASE INDEPENDENTLYOF SRC FAMILY KINASE INHIBITION
A. E. Schade* (US), E. Shick

PP-WE-096SIMVASTATIN INHIBITS TXA2 SYNTHESIS IN PLATELETS REGULATING CPLA2 PHOSPHORYLATION AND CALCIUM MOVEMENTS
A. Moscardo* (ES), M. T. Santos, B. Cortina, A. Latorre, J. Valles

PP-WE-097 MODERATE PHARMACOLOGICAL PLATELET COUNT REDUCTION PREVENTS ACUTE THROMBOTIC VASCULAR GRAFT OCCLUSION IN PRIMATES
E. I. Tucker* (US), U. M. Marzec, S. Hurst, A. Gruber, S. R. Hanson

PP-WE-098 PRODUCTION OF A RECOMBINANT PUTATIVE INHIBITOR OF PLATELET AGGREGATION FROM HAEMENTERIA DEPRESSA LEECH
F. Faria* (BR), J. Lacerda-Alves, A. M. Chudzisnki-Tavassi

PP-WE-099 CONSTRUCTION AND CHARACTERIZATION OF A CHIMERIC ANTI-PLATELET GLYCOPROTEIN IB ALPHA MONOCLONAL ANTIBODY
J. Yang* (CN), S. Ji, N. Dong, C. Ruan

PP-WE-100 BLEEDING RESPONSE INDUCED BY ANTI-THROMBOTIC DOSES OF PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR IN MICE
J. E. Bird* (US), P. L. Smith, J. S. Bostwick, W. A. Schumacher

PP-WE-101 P2RY1 GENE POLYMORPHISMS ARE ASSOCIATED WITH ASPIRIN RESISTANCE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
P. P. Aung, G. Murugesan, L. Zhang, J. Barnard, Y. Hu, Q. Wang, K. Kottke-Marchant* (US)

PP-WE-102 BRIEF ANTECEDENT ‘PRECONDITIONING’ ISCHEMIA ATTENUATES RECURRENT PLATELET-MEDIATED THROMBOSIS: LOSS OF EFFICACY IN AGING RATS
K. Przyklenk* (US), P. Whittaker

PP-WE-103 DISPERSAL OF PLATELET AGGREGATES BY P2Y12 ANTAGONIST ARC-69931MX
H. E. Speich, J. D. Caughran, L. T. Lands, L. K. Jennings* (US)

PP-WE-105 VITAMIN C INFUSION BLUNTS CD40L UP-REGULATION IN PATIENTS UNDERGOING CORONARY STENT
P. Pignatelli* (IT), S. Basili, G. Tanzilli, R. Carnevale, S. di Santo, L. Loffredo, A. Celestini, E. Mangieri, F. Violi

PP-WE-106 A SMALL MOLECULE INHIBITOR OF P2Y1 BLOCKS ADP-INDUCED AGGREGATION BUT NOT SHAPE CHANGE VIA AN ALLOSTERIC MECHANISM
R. Mairuhu* (US), L. Dowal, J. R. Dilks, P. Blair, R. Flaumenhaft

PP-WE-107 FIBRIN PRESENCE AND TISSUE FACTOR EXPRESSION IN AORTIC VALVES IN PATIENTS WITH AORTIC STENOSIS AND AORTIC INSUFFICIENCY: ASSOCIATION WITH PLASMA MARKERS OF FIBRIN TURNOVER AND THROMBIN GENERATION
A. Undas* (PL), J. Natorska, G. Marek, M. Hlawaty, J. Sadowski, W. Tracz

PP-WE-108 DETECTION OF TISSUE FACTOR ACTIVITY IN WHOLE BLOOD BY A FLUOROGENIC THROMBIN GENERATION ASSAY
E. Coll* (US), A. Amirkhosravi, J. Francis

PP-WE-109 INTRACELLULAR PROCESSING AND SECRETION OF COAGULATION FACTOR VII STUDIED BY PULSE-CHASE ANALYSIS
G. Bolt* (DK), T. D. Steenstrup, C. Kristensen

PP-WE-110 IMPACT OF ANTICOAGULANTS ON PLATELET-MONOCYTE COMPLEX FORMATION AND REGULATION OF PROCOAGULANT FUNCTION OF MONOCYTES ISOLATED FROM HUMAN BLOOD
G. B. Manjunath* (NO), F. X. Gruber, M. Sovershaev, B. Østerud, J. Hansen

PP-WE-111 EVALUATION OF A NEW AUTOMATED ANALYSER FOR HAEMOSTASIS AND THROMBOSIS ANALYSIS
J. Needham* (UK), H. Lewis, S. Rangarajan, A. Roy

PP-WE-112 LOCAL ANESTHETICS ATTENUATE TISSUE FACTOR EXPRESSION IN ACTIVATED MONOCYTES VIA NF-KB-MEDIATED INHIBITION OF MRNA SYNTHESIS
J. Kim* (KR), K. Kim, K. Han, H. Kim

PP-WE-113 METFORMIN DECREASES FACTOR VII EXPRESSION
J. A. Carew* (US), K. R. Cronin

PP-WE-114 EVALUATION OF THE ENDOGENOUS THROMBIN POTENTIAL (ETP) ASSAY
J. P. Antovic* (SE), A. Kallner, N. M. H. Soutari, M. Sten-Linder

PP-WE-115 THE IMPACT OF LOCAL MEAN NORMAL PROTHROMBIN TIME VARIABILITY ON INR WITH LESS RESPONSIVE THROMBOPLASTIN REAGENTS AS DEMONSTRATED BY LOCAL ISI CALIBRATION WITH A NEW SET OF CERTIFIED PLASMAS
J. Hammelburger* (US), R. Bottenus, M. Triscott, M. Johnston, M. Lauzon

PP-WE-116 A POSITIVE APTT BIPHASIC WAVE FORM IS AN EARLY PREDICTOR OF RENAL IMPAIRMENT IN PATIENTS ON THE INTENSIVE CARE UNIT
K. Sullivan* (UK), J. Thachil, C. Downey, T. Dutt, J. Harper, C. H. Toh

PP-WE-117 CLINICAL AND LABORATORY EVALUATIONS OF A HIGH-SENSITIVITY LIQUID HUMAN THROMBOPLASTIN FOR USE WITH AUTOMATED COAGULATION ANALYZERS
K. M. Cawthern* (US), R. Bottenus, J. Vasquez, D. Diaz, M. X. Triscott

PP-WE-118 ENDOGENOUS THROMBIN POTENTIAL AS A NOVEL METHOD FOR CHARACTERISATION OF PROCOAGULANT SNAKE VENOMS
L. F. Lincz* (AU), D. Woods, S. Alley, M. A. O’Leary, M. Seldon, G. Isbister

PP-WE-119 ANIONIC LIPID DOMAIN FORMATION ON THE NANOMETER SCALE
M. A. McLean* (US), I. G. Denisov, S. G. Sligar

PP-WE-120 FACTOR VII ACTIVATION BY FACTOR IXa-ALPHA VERSUS FACTOR IXa-BETA
M. L. Morgret* (US), J. H. Morrissey

PP-WE-121 INVERSE CORRELATION BETWEEN PLASMA AND PLATELET CHOLESTEROL CONCENTRATION WITH PLATELET TISSUE FACTOR-DEPENDENT CLOTTING ACTIVITY
O. Panes* (CL), V. Matus, M. Acevedo, J. Pereira, D. Mezzano

PP-WE-122 DETECTING TISSUE FACTOR-POSITIVE CELLS IN A MIXED POPULATION BY SCANNING ELECTRON MICROSCOPY
V. Strogolov* (US), L. G. Westrick, J. A. Oliver

PP-WE-123 THE COMMON AND FUNCTIONAL F12 -4 C>T POLYMORPHISM COUPLED WITH LOW FXII LEVELS SIGNIFICANTLY ASSOCIATED WITH REDUCED FVIIC AND FIXC LEVELS, PROLONGED APTT, AND LESS THROMBIN GENERATION
J. Corral* (ES), A. I. Antón, T. Quiroga, R. González-Conejero, J. Pereira, V. Roldán, V. Vicente, D. Mezzano

PP-WE-124 THE IMPACT OF COLLECTION TUBE FILL VOLUME ON INTERNATIONAL NORMALISED RATIO
J. J. Potgieter* (ZA), R. Pool, E. M. D. Botha, A. Prinsloo, S. Olorunju

PP-WE-125 THROMBIN GENERATION: CORN TRYPSIN INHIBITOR CHANGES RELATIONSHIPS BETWEEN NORMAL AND THROMBOTIC SAMPLES
J. K. Ryland* (UK), A. S. Lawrie, S. J. Machin, I. J. Mackie

PP-WE-126 CHANGES OF INHIBITORY COMPLEXES OF THE PLASMA KALLIKREIN-KININ SYSTEM FOLLOWING PERCUTANEOUS CORONARY INTERVENTION OR THROMBOLYTIC THERAPY WITH TENECTEPLASE
J. W. P. Govers-Riemslag* (NL), V. Pönitz, T. Brügger-Andersen, H. Grundt, H. ten Cate, D. W. T. Nilsen

PP-WE-127 DOES FACTOR XI ACTIVITY CORRELATE WITH THROMBIN GENERATION
L. Elreda* (US), O. U. Ogbata, M. Drejka, A. J. Cohen

PP-WE-128 TOTAL LAB AUTOMATION AND COAGULATION TESTING
M. Deckers* (NL), G. Bulut, T. Hofman, J. de Kok

PP-WE-129 BIOLOGICAL EVALUATION OF SYNTHETIC LINEAR ANALOGUE PEPTIDES OF 18111818 LOOP OF THE A3 SUBUNIT OF THE LIGHT CHAIN A3-C1-C2 OF FVIII BLOOD COAGULATION
M. P. Makris* (GR), K. Patsialas, C. Koutsas, M. Liakopulu, P. E. Makris

PP-WE-130 INSIGHTS INTO THE MECHANISM UNDERLYING POLYPHOSPHATE STIMULATED AUTOACTIVATION OF FACTOR XII
R. Engel, R. A. S. Ariens, H. Philippou, N. J. Mutch* (UK)

PP-WE-131 GENETIC POLYMORPHISM OF BLOOD COAGULATION FACTOR IX GENE IN GREEK PATIENTS WITH THROMBOPHILIA
M. S. Iskas, R. M. Papi, G. E. Mimikakou, D. A. Kyriakidis, P. E. Makris* (GR)

PP-WE-132 FACTOR VIII LEVELS DURING AND AFTER ORAL ANTICOAGULANT THERAPY
S. Passamonti, I. Martinelli, P. Bucciarelli* (IT), P. M. Mannucci

PP-WE-133 STANDARDIZATION OF THROMBIN GENERATION TEST – II. WHICH REFERENCE PLASMA FOR TGT? : AN INTERNATIONAL MULTIleft STUDY
Y. Dargaud* (FR), R. Luddington, E. Gray, V. Regnault, T. Siegemund, T. Baglin, J. Hogwood, T. Lecompte, A. Siegemund, C. Negrier

PP-WE-134 INHIBITION OF THROMBIN VERSUS FACTOR Xa FOR VENOUS THROMBUS REDUCTION
B. C. Cooley* (US)

PP-WE-135 EFFECT OF LMWH OF FIRST AND SECOND GENERATION ON THE THROMBIN GENERATION (TG) PARAMETERS
C. L. Duboscq* (AR), J. J. Ceresetto, C. Shanley, G. Stemmelin, O. Rabinovich, C. Doti, N. Cazap, E. Bullorsky

PP-WE-136 ENDOTHELIAL PROTEIN C RECEPTOR GENE SILENCING AFFECTS MDA-MB-231 BREAST CANCER CELL INVASIVENESS
G. Fontana, C. Razzari, S. Ferrero, E. M. Faioni* (IT)

PP-WE-137 MONITORING OF LOW MOLECULAR WEIGHT HEPARIN IN PATIENTS WITH CHRONIC RENAL FAILURE BY USING CPM
E. Vlasova* (RU), I. Vasilenko, V. Suslov

PP-WE-138 INFLUENCE LOW MOLECULAR WEIGHT HEPARIN ON PLATELETS
E. Vlasova* (RU), I. Vasilenko, V. Samoylenko, V. Suslov

PP-WE-139 A NOVEL METHOD TO ANALYZE ENDOTHELIAL CELL PROTEIN C RECEPTOR EXPRESSION IN VITRO
E. Ducros* (FR), S. Mirshahi, C. Bermot, M. Mirshahi

PP-WE-140 THE EFFECTS OF PHOSPHOLIPID AND TISSUE FACTOR CONCENTRATIONS ON THE APC ANTICOAGULANT ACTIVITY IN A THROMBIN GENERATION ASSAY
G. Salvagno* (IT), G. Lippi, M. Franchini, G. Guidi, B. Dahlback

PP-WE-141 INFECTIVITY AND POSSIBLE GAIN OF FUNCTION OF P1 MUTANTS OF ANTITHROMBIN
I. Martínez-Martínez* (ES), A. Ordóñez, A. Miñano, L. Velázquez, R. Teruel, J. Padilla, C. Martínez, R. Lecumberri, H. Cano, C. de Cos, V. Vicente, J. Corral

PP-WE-142 LABORATORY MONITORING OF DABIGATRAN DURING ORTHOPEDIC SURGERY
J. Ulehlova* (CZ), L. Slavik, V. Krcova, J. Prochazkova, A. Hlusi, L. Cech

PP-WE-143 MOLECULAR AND FUNCTIONAL HETEROGENEITY IN CONTAMINANTS ISOLATED FROM RECALLED HEPARIN. IMPACT ON ANTICOAGULATION AND POTENTIAL ADVERSE REACTIONS
J. Fareed* (US), D. Hoppensteadt, W. Jeske, C. Adiguzel, O. Iqbal, J. Walenga

PP-WE-144 EVALUATION OF A NOVEL QUANTITATIVE ASSAY FOR FACTOR V LEIDEN (FVL)
K. P. Hickey* (UK), P. C. Cooper, S. Kitchen

PP-WE-145 C1173T POLYMORPHISM IN THE VKORC1 GENE AND WARFARIN SENSITIVITY
L. A. Bastos* (AR), A. N. Blanco, S. Meschengieser, M. A. Lazzari

PP-WE-146 FREQUENCY OF VKORC1 POLYMORPHISM C1173T IN A GROUP OF NORMAL INDIVIDUALS AND PATIENTS UNDER ANTICOAGULANT TREATMENT IN ARGENTINA
L. A. Bastos* (AR), A. N. Blanco, S. Meschengieser, M. A. Lazzari

PP-WE-147 THROMBIN GENERATION IN CARRIERS OF INHERITED CLOTTING INHIBITORS DEFECTS
V. Rossetto* (IT), L. Spiezia, G. Sabrina, P. Dabrilli, C. Abalotti, S. Barbar, D. Tormene, P. Simioni

PP-WE-148 SUBSTRATE SPECIFICITY OF NATTOKINASE : APPLICATION TO THE ASSAY OF ITS POTENCY
H. Sumi* (JP), C. Yatagai, S. Naito, T. Ohsugi, J. Saito

PP-WE-149 FERMENTATION OF ROYAL JELLY AND BEE POLLEN : NATTOKINASE FIBRINOLYSIS AND VITAMIN K2 CONTENT
H. Sumi* (JP), M. Imai, Y. Yanagisawa

PP-WE-150 INFLUENCE OF FACTOR X ON IN VITRO AND IN VIVO GENE DELIVERY BY AD5 AND AD35 VECTORS
J. A. Greig, S. N. Waddington, S. M. K. Buckley, A. L. Parker, D. Bhella, R. Pink, T. Morita, J. Custers, J. Goudsmit, S. A. Nicklin, J. H. McVey* (UK), A. H. Baker

PP-WE-151 SELECTED MODIFICATION OF THE ADENOVIRUS TYPE 5 HEXON MODULATES INTERACTION WITH COAGULATION FACTOR X AND HEPATOCYTE TRANSDUCTION IN VIVO
R. Alba, A. C. Bradshaw, A. L. Parker, D. Bhella, S. A. Nicklin, S. N. Waddington, J. Custers, J. Goudsmit, N. van Rooijen, D. H. Barouch, J. H. McVey* (UK), A. H. Baker

PP-WE-152 THE INFLUENCE OF GLYCOSYLATION ON TISSUE FACTOR ACTIVITY
J. Krudysz-Amblo* (US), K. G. Mann, S. Butenas

PP-WE-153 MAPPING FACTOR VIII C1 DOMAIN AMINO ACIDS THAT COOPERATE WITH EPITOPES OF THE C2 DOMAIN IN MEMBRANE BINDING
J. Lu* (US), S. W. Pipe, H. Z. Miao, M. G. Jacquemin, G. E. Gilbert

PP-WE-154 EFFECT OF ANTITHROMBIN (AT) COMPLEX FORMATION ON THE PHARMACOKINETICS OF RECOMBINANT FACTOR VIIa (RFVII) AND NN1731 IN BEAGLE DOGS
L. C. Petersen* (DK), D. M. Karpf, H. Pelzer, M. B. Hermit, M. Ezban

PP-WE-155 ENDOTHELIAL PROTEIN C RECEPTOR AND PROTEASE ACTIVATED RECEPTOR 1 ARE REQUIRED FOR NEUROPROTECTIVE ACTION OF ACTIVATED PROTEIN C
L. Gorbacheva* (RU), O. Davidova, V. Pinelis, G. Reiser, S. Strukova

PP-WE-156 THROMBIN RESIDUES IN THE BETA-INSERTION LOOP AND THE S2 POCKET CONTRIBUTE TO RECOGNIZING FACTOR XIII ACTIVATION PEPTIDES
M. A. Jadhav* (US), R. C. Lucas, M. C. Maurer

PP-WE-157 IDENTIFICATION AND CHARACTERISATION OF FACTOR VIII-MEMBRANE INTERACTION INHIBITORS
M. Kulharia* (FR), O. Sperandio, J. Voorberg, S. Wielders, J. Rosing, B. O. Villoutreix, G. A. F. Nicolaes

PP-WE-158 CONFORMATIONAL CHANGES THAT OCCUR WHEN THROMBIN BINDS EXOSITEDIRECTED LIGANDS IN SOLUTION
M. V. Malovichko* (US), T. M. Sabo, M. C. Maurer

PP-WE-159 SUBSTRATE SPECIFICITY OF VKORC1
M. Marinova* (DE), M. Watzka, P. Westhofen, M. Hass, D. Luetjohann, J. Oldenburg

PP-WE-160 ADHESIVES PROPERTIES OF A HEMOLIN FROM LONOMIA OBLIQUA CATERPILLAR BRISTLES AND MECHANISMS OF ACTIVATION OF HUMAN FACTOR X
M. P. Flores* (BR), O. H. Ramos, A. M. Chudzinski-Tavassi

PP-WE-161 TRANSCRIPTIONAL REGULATION OF PROTEIN Z
M. Ben-Hasan* (UK), P. R. Winship, A. J. Hall

PP-WE-162 BINDING OF THE C2 DOMAIN OF FACTOR V AND FACTOR VIII TO ANIONIC PHOSPHOLIPID BILAYERS
Y. Z. Ohkubo* (US), E. Tajkhorshid

PP-WE-163 NATURAL ANTICOAGULANTS CAN BE USEFUL PREDICTORS OF SEVERITY IN CHRONIC LIVER DISEASE
A. M. Abdelgadir* (SA), A. A. Abdo, F. M. Al Sania, N. Azzam, K. Al Sawat, M. Al Duhgyal, A. K. Al Ghumlas, A. Hersi

PP-WE-164 THE USE OF POLYBRENE FOR HEPARIN NEUTRALISATION IN THE THROMBIN GENERATION TEST
A. Carlo* (FR), E. Arnaud, B. J. Woodhams

PP-WE-165 VENOUS THROMBOSIS RELATED TO RESISTANCE TO TISSUE FACTOR PATHWAY INHIBITOR
B. Tardy- Poncet* (FR), M. Piot, C. Chapelle, P. Morange, J. Reynaud, K. Rivron-Guillot, O. Garraud, L. Campos, H. Decousus, P. Mismetti, B. Tardy

PP-WE-166 INCREASED LEVELS OF ANAPHYLATOXIN (C5A) AND BRADYKININ IN END-STAGE RENAL DISEASE PATIENTS ON MAINTENANCE HEMODIALYSIS. POTENTIAL RELEVANCE TO HEPARIN MEDIATED HEMODYNAMIC RESPONSES
C. Adiguzel* (US), V. Bansal, E. Litinas, D. Hoppensteadt, J. Fareed

PP-WE-167 INHIBITORY POWERS MOLECULES OF SPECIFICS SITES IN THE HAEMOSTATIC SYSTEM FROM SALIVARY GLANDS LEECH HAEMENTERIA VIZOTTOI (VIZOTTO, 1967)
D. G. L. Oliveira* (BR), A. Miranda, A. M. Chudzinski-Tavassi

PP-WE-168 EFFECT OF NU172 AND BIVALIRUDIN ON ECARIN CLOTTING TIME IN HUMAN PLASMA AND WHOLE BLOOD
E. K. Waters* (US), J. Richardson, R. G. Schaub, J. C. Kurz

PP-WE-169 COMPONENTS OF VARIABILITY OF ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) VS. ANTI-FACTOR Xa (AXa) ON UNFRACTIONATED HEPARIN (UFH) DOSE ADJUSTMENTS
F. Guerrero* (FR), A. Faure, V. Diemert, S. Voisin, P. Sié, A. Bura Rivière

PP-WE-170 THROMBIN GENERATION IN PATIENTS (PTS) WITH SEVERE SEPSIS AND SEPTIC SHOCK DURING THE TREATMENT WITH HIGH DOSES OF ANTITHROMBIN III (AT)
G. M. Galstyan* (RU), A. V. Krechetova, M. G. Alexanyan, E. I. Sinauridze, V. M. Gorodetsky, S. A. Vasiliev

PP-WE-171 USE OF ALBUMIN TO REPLACE FVIII DEFICIENT PLASMA IN THE BETHESDA ASSAY FOR FACTOR VIII INHIBITORS: COMPARISON TO THE NIJMEGEN BETHESDA ASSAY
G. W. Kershaw* (AU), D. Jayakodi, A. Belin, S. Dunkley, D. Joshua

PP-WE-172 EXPOSURE DEPENDENT EFFECTS ON COAGULATION ASSAYS BY THE ORAL DIRECT THROMBIN INHIBITOR AZD0837 IN PATIENTS WITH ATRIAL FIBRILLATION. RESULTS FROM TWO PHASE II STUDIES
G. Y. H. Lip* (UK), B. Olsson, L. H. Rasmussen, A. Tveit, E. Jensen, U. G. Eriksson, M. Elg, P. Weissman, K. Wåhlander

PP-WE-173 ANTICOAGULANT MECHANISMS OF ANTITHROMBIN-HEPARIN STUDIED BY TEG
H. M. Atkinson* (CA), T. A. Mewhort-Buist, L. R. Berry, A. K. C. Chan

PP-WE-174 NOVEL HEPARIN COFACTOR II-DERMATAN SULFATE COVALENT COMPLEX FORMATION SELECTS FOR DERMATAN SULFATE WITH HIGHER MOLECULAR WEIGHT
H. H. W. Chan* (CA), D. L. French, L. R. Berry, A. K. C. Chan

PP-WE-175 ANTITHROMBIN ALA383PRO: A NEW MISSENSE VARIANT IDENTIFIED IN A PATIENT WITH VENOUS THROMBOSIS
I. Tirado* (ES), M. Borrell, D. Llobet, I. Coll, C. Vallvé, P. Fuentes, J. Mateo, J. Fontcuberta

PP-WE-176 LOW MOLECULAR WEIGHT HEPARIN INHIBITS TUMOR ASSOCIATED ANGIOGENESIS IN VIVO
I. M. C. Debergh* (BE), N. van Damme, P. Pattyn, M. Peeters, W. P. Ceelen

PP-WE-177 COVALENTLY LINKING ANTITHROMBIN TO HEPARIN ENHANCES THE INHIBITION OF FXa IN THE PROTHROMBINASE COMPLEX
I. Stevic* (CA), T. A. Kentner, L. R. Berry, A. K. C. Chan

PP-WE-178 PHARMACOKINETICS AND SAFETY OF A NOVEL ULTRA LOW MOLECULAR WEIGHT HEPARIN (RO-14) IN HEALTHY VOLUNTEERS – A FIRST TIME IN HUMAN (FTIH) SINGLE ASCENDING DOSE STUDY
R. M. Antonijoan, S. Rico, M. Puntes, M. Borrell, J. Fontcuberta, M. Monreal, J. Martinez-Gonzalez* (ES), M. J. Barbanoj

PP-WE-179 THE FACTOR Xa INHIBITOR DU-176B IS SAFE IN HEALTHY SUBJECTS 24 HOURS POST WARFARIN TREATMENT: A RANDOMIZED, DOUBLE-BLIND STUDY
J. Mendell* (US), R. J. Noveck, I. Rubets, R. Luo, M. Shi, D. Salazar

PP-WE-180 IN-VITRO CHARACTERISATION OF A BIVALENT FUSION APTAMER TARGETING HUMAN THROMBIN
J. Müller* (DE), B. Wulffen, G. Mayer, B. Pötzsch

PP-WE-181 EFFECTS OF DIRECT THROMBIN OR FACTOR Xa INHIBITION ON CLOT THROMBOGENICITY IN VITRO: COMPARISON OF DABIGATRAN WITH RIVAROXABAN AND APIXABAN
J. van Ryn* (DE), M. Kink-Eiband, I. Kuritsch, W. Wienen

PP-WE-182 ATTITUDES TOWARDS TREATMENT WITH VITAMIN-K ANTAGONISTS IN RELATION TO PERSONALITY TRAITS IN PATIENTS ON STABLE ORAL ANTICOAGULANT THERAPY
M. Felten, J. Harenberg* (DE), L. Frölich, C. Weiss

PP-WE-183 GENETIC POLYMORPHISMS OF VKORC1 AND CYP2C9 CONTRIBUTES TO STEADYSTATE DOSE REQUIREMENTS OF PATIENTS ON PHENPROCOUMON
J. Harenberg* (DE), W. Wu, C. Weiss, S. Stehle, J. Kirchheiner, U. Fuhr, C. Gleiter

PP-WE-184 FUCOSYLATED CHONDROITIN SULFATE INHIBITS PLASMA THROMBIN GENERATION VIA TARGETING OF THE FACTOR IXa HEPARIN-BINDING EXOSITE
J. P. Sheehan* (US), Y. Buyue

PP-WE-185 ECT MEASUREMENT AFTER DIFFERENT STORAGE CONDITIONS OF AR-H067637, THE ACTIVE METABOLITE OF AZD0837, IN WHOLE BLOOD AND PLASMA
K. Wåhlander* (SE), F. Wågberg, M. Elg

PP-WE-186 EFFECTS OF CYTOCHROME P450 2C9 (CYP2C9) AND VITAMIN K EPOXIDE REDUCTASE (VKORC1) GENOTYPES ON FLUINDIONE ANTICOAGULATION STATUS
K. Lacut* (FR), C. Verstuyft, L. Gourhant, E. Poulhazan, L. Becquemont, D. Mottier

PP-WE-187 PROTAMINE INHIBITS PROPAGATION OF THROMBIN GENERATION
K. A. Tanaka* (US), D. Bolliger, J. H. Levy, F. Szlam

PP-WE-188 ASSOCIATION OF THE SINGLE NUCLEOTIDE POLYMORPHISM RS2227589 IN THE SERPINC1 GENE WITH INHERITED ANTITHROMBIN DEFICIENCY
K. Jochmans* (BE), C. Orlando, W. Lissens, I. Liebaers, M. de Waele

PP-WE-189 ANTIDOTE REVERSAL OF A NOVEL PROTHROMBIN APTAMER ANTICOAGULANT
K. M. Bompiani* (US), S. Oney, F. C. Church, B. A. Sullenger

PP-WE-190 COMPARISON OF DABIGATRAN, UNFRACTIONATED HEPARIN AND LOW MOLECULAR-WEIGHT HEPARIN IN PREVENTING THROMBUS FORMATION ON MECHANICAL HEART VALVES: RESULTS OF AN IN VITRO STUDY
L. Maegdefessel* (DE), T. Linde, F. Krapiec, U. Steinseifer, J. van Ryn, B. Hauroeder, U. Raaz, M. Buerke, K. Werdan, A. Schlitt

PP-WE-191 MECHANISM UNDERLYING PROTEIN C DEFICIENCY IN A PATIENT WITH AN ALA267THR MUTATION
L. Tjeldhorn* (NO), N. Iversen, P. Sandset, G. Skretting

PP-WE-192 WHAT IS THE BEST WAY HOW TO MONITOR TINZAPARIN TREATMENT? A COMPARISON BETWEEN ASSAYS
L. Lanning* (UK), A. Riddell, A. Griffioen, S. Brooks, P. Chowdary, A. Gatt

PP-WE-193 COVALENT LINKAGE OF HEPARIN TO ANTITHROMBIN INCREASES LUNG CELL PROLIFERATION
L. R. Berry* (CA), I. Tseu, M. Post, A. K. C. Chan

PP-WE-194 EFFECT OF SUBSTRATE AND ANTICOAGULANT ON THE FLUOROGENIC DETECTION OF DYNAMIC THROMBIN ACTIVITY IN WHOLE BLOOD
M. S. Chatterjee* (US), S. L. Diamond

PP-WE-195 PERFORMANCE OF A NEW KCT ASSAY AND COMPARISON TO THE DRVVT FOR DETECTION OF LA
M. D. Goldford* (US), S. R. Raval

PP-WE-196 RANDOMIZED, PARALLEL GROUP, WARFARIN CONTROL, MULTIleft PHASE II STUDY EVALUATING SAFETY OF DU-176B IN JAPANESE SUBJECTS WITH NON VALVULAR ATRIAL FIBRILLATION (NVAF)
M. Yasaka* (JP), H. Inoue, Y. Kawai, T. Yamaguchi, S. Uchiyama, M. Matsumoto, S. Ogawa, Y. Koretsune, T. Yamashita

PP-WE-197 VENOUS THROMBOEMBOLISM PROPHYLAXIS METHODS IN THE TRAUMA AND EMERGENCY SURGERY INTENSIVE CARE UNIT PATIENTS
M. Kurtoglu* (TR), K. Serin, H. Yanar, Y. Ozdenkaya

PP-WE-198 EFFECTS OF RIVAROXABAN, A NOVEL, ORAL, DIRECT FACTOR Xa INHIBITOR, ON COAGULATION ASSAYS
M. M. Samama* (FR), L. L. Fem, C. Guinet, E. Perzborn, J. Martinoli, F. Depasse

PP-WE-199 SUITABILITY OF CHROMOGENIC ANTI-FACTOR Xa METHODS TO MEASURE RIVAROXABAN IN HUMAN PLASMA
M. M. Samama* (FR), L. L. Flem, C. Guinet, E. Perzborn, J. Amiral, F. Depasse

PP-WE-200 EFFECTS OF THE ORAL DIRECT THROMBIN INHIBITOR AZD0837 AND VKA ON FIBRIN FORMATION IN A PERFUSION CHAMBER MODEL OF THROMBOSIS IN PATIENTS WITH ATRIAL FIBRILLATION
M. Wolzt* (AT), S. Kapiotis, K. Schützer, M. Holmberg, U. Eriksson, K. Wahlander

PP-WE-201 DOSE-DEPENDENT INHIBITION OF EX VIVO FIBRIN FORMATION BY THE ORAL DIRECT THROMBIN INHIBITOR AZD0837 IN PATIENTS WITH ATRIAL FIBRILLATION
M. Wolzt* (AT), S. Kapiotis, K. Schützer, M. Holmberg, U. Eriksson, K. Wahlander

PP-WE-202 ROLE OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AS A PREDICTOR OF DISSEMINATED INTRAVASCULAR COAGULOPATHY (DIC) AMONG CHILDREN WITH SEPSIS SYNDROME
M. A. F. Ragab* (EG), F. M. Hafez

PP-WE-203 PROPHYLACTIC TREATMENT WITH RECOMBINANT ACTIVATED FACTOR VII IN PAEDIATRIC PATIENTS WITH HAEMOPHILIA A AND INHIBITORS
M. A. Cermelj* (AR), A. M. Ferro, S. M. Ouvina, J. A. Pollola, G. B. Paoloski

PP-WE-204 DELAY IN INITIATING PROPHYLACTIC TREATMENT WITH DABIGATRAN ETEXILATE FOLLOWING TOTAL HIP OR KNEE REPLACEMENT SURGERY DID NOT AFFECT EFFICACY. POOLED ANALYSIS OF TWO EUROPEAN PHASE III TRIALS
O. E. Dahl* (NO), A. A. Kurth, N. Rosencher, J. M. Schnee, A. Clemens, S. Hantel, B. I. Eriksson

PP-WE-205 DABIGATRAN ETEXILATE 150 MG ONCE DAILY FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE OR HIP REPLACEMENT SURGERY IN THE ELDERLY AND THOSE WITH MODERATE RENAL IMPAIRMENT
O. E. Dahl* (NO), A. A. Kurth, N. Rosencher, A. Clemens, M. Feuring, H. Noack, B. I. Eriksson

PP-WE-206 PROPHYLACTIC FIBRINOGEN INFUSION REDUCES BLEEDING AFTER CORONARY ARTERY BYPASS SURGERY: A PROSPECTIVE RANDOMIZED PILOT STUDY
F. Baghaei* (SE), M. Karlsson, L. Ternström, M. Hyllner, A. Flinck, S. Skrtic, A. Jeppsson

PP-WE-207 INTER-RELATIONSHIP OF DIRECT THROMBIN INHIBITOR CONCENTRATIONS WITH THROMBIN CONCENTRATION AND CLAUSS FIBRINOGEN LEVELS
J. B. Callahan* (US), K. Distasio, H. Lin, M. Doyle, M. Triscott

PP-WE-208 SEX-SPECIFIC GENETIC DETERMINATION OF FIBRINOGEN PLASMA LEVELS
M. Sabater-Lleal, I. Arbesú, A. Buil, J. Souto, J. Blangero, J. Fontcuberta, L. Almasy, J. Soria* (ES)

PP-WE-209 GENETIC VARIANTS UNDERLAYING FIBRINOGEN LEVELS: FROM LINKAGE ANALYSIS TO FINE MAPPING ON CHROMOSOME 12Q24
I. Arbesú, M. Sabater-Lleal, A. Buil, J. Souto, S. Lopez, L. Rib, J. Blangero, J. Fontcuberta, L. Almasy, J. Soria* (ES)

PP-WE-210 GENETIC, LABORATORY AND CLINICAL CHARACTERIZATION OF 45 FAMILIES WITH CONGENITAL DYSFIBRINOGENEMIA
K. Sittinger* (DE), W. Miesbach, C. Heller, D. Weiss, A. Lauricella, M. Vega-Ostertag, C. Bidlingmaier, U. Harbrecht, C. Sucker, B. Zieger, E. Seifried, J. Oldenburg, C. Geisen

PP-WE-211 IMPAIRED THROMBIN SCAVENGING MAY LEAD TO THROMBOEMBOLIC COMPLICATIONS IN AFIBRINOGENEMIA: A CASE REPORT
K. Peter* (CH), S. Gretener, B. Laemmle, F. Demarmels Biasiutti, L. Alberio

PP-WE-212 ALA312THR POLYMORPHISM IS NOT ASSOCIATED WITH CHANGES IN CLOT STRUCTURE IN A RECOMBINANT SYSTEM: PITFALLS IN ANALYZING PLASMAPURIFIED PROTEIN
K. F. Standeven* (UK), S. Dolling, F. P. Phoenix, K. Gersh, J. W. Weisel, R. A. S. Ariens, R. A. Ajjan

PP-WE-213 FUNCTIONAL CHARACTERIZATION OF FIBRINOGEN POZNAN: A PREMATURE TRUNCATING MUTATION IN FGG ASSOCIATED WITH HYPOFIBRINOGENEMIA AND MILD BLEEDING TENDENCY
K. Zawilska* (PL), A. Undas, L. Malendowicz-Portala, P. de Moerloose, R. Fish, M. Neerman-Arbez

PP-WE-214 GENETIC MUTATIONS ASSOCIATED WITH DYSFIBRINOGENEMIA IN A UK COHORT
M. Hill* (UK), R. C. Tait, M. Williams, G. Dolan

PP-WE-215 FIBRINOGEN BIRMINGHAM II - A NOVEL VARIANT ASSOCIATED WITH HYPODYSFIBRINOGENEMIA, DUE TO COMPOUND HETEROZYGOSITY FOR TRP334CYS AND ASN335TYR IN THE FIBRINOGEN A ALPHA CHAIN
M. Hill* (UK), N. Thompson, B. Gordon, R. Ajjan, R. A. S. Ariens, M. Williams, G. Dolan

PP-WE-216 FIBRIN IN BLOOD CLOTS FORMS NATURAL AMYLOID
B. Bouma, C. Maas, L. M. J. Kroon-Batenburg, O. Kranenburg, Y. Wu, M. F. B. G. Gebbink* (NL)

PP-WE-217 EVALUATION OF MARKERS OF INFLAMMATION, HEMOSTASIS AND FIBRINOLYSIS IN OBESE ASTHMATIC ADOLESCENTS
F. Huang* (MX), B. Del-Rio-Navarro, J. Perez-Ontiveros, S. Torres-Alcantara, Toussaint-Martinez de Castro

PP-WE-218 REPROGRAMMED STREPTOKINASES DEVELOP FIBRIN-TARGETING AND DISSOLVE BLOOD CLOTS WITH MORE POTENCY THAN TISSUE PLASMINOGEN ACTIVATOR
I. Y. Sazonova* (US), R. A. McNamee, A. K. Houng, S. M. King, L. Hedstrom, G. L. Reed

PP-WE-219 MARKERS OF FIBRINOLYSIS IN FIRST-EVER LACUNAR STROKE
I. L. H. Knottnerus* (NL), J. W. P. Govers-Riemslag, K. Hamulyak, R. van Oerle, R. P. W. Rouhl, H. M. H. Spronk, J. Staals, H. ten Cate, J. Lodder, R. J. van Oostenbrugge

PP-WE-220 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR IN PATIENTS WITH DIABETES MELLITUS TYPE 2
J. Stasko* (SK), P. Chud?, P. Holl?, P. Galajda, P. Kubisz

PP-WE-221 ABNORMALITIES IN FIBRINOLYTIC FACTORS CONTRIBUTE TO HYPERCOAGULABLE STATES AND ARE QUANTIFIABLE UTILIZING THE OVERALL HAEMOSTATIC POTENTIAL (OHP) ASSAY
J. L. Curnow* (AU), M. C. Morel-Kopp, C. M. Ward

PP-WE-222 NORMALIZATION OF CYTOKINES IN PULMONARY HYPERTENSION IN MICE DEFICIENT IN THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR
J. Morser* (JP), P. Gil Bernabe, S. Aoki, L. Qin, D. Boveda Ruiz, T. Takagi, C. N. D’Alessandro-Gabazza, O. Taguchi, Y. Takei, E. C. Gabazza

PP-WE-223 HYPERFIBRINOLYSIS AND KYNURENINE PATHWAY IN CHRONIC RENAL FAILURE PATIENTS
K. Pawlak* (PL), A. Buraczewska-Buczko, M. Mysliwiec, D. Pawlak

PP-WE-224 URINE FIBRINOLYTIC ACTIVITY IN ELDERLY PATIENTS WITH HYPERTENSION
L. V. Podorolskaya* (RU), L. A. Alekseeva, E. L. Chumakova

PP-WE-225 PRELIMINARY CRYSTALLOGRAPHIC STUDY OF HUMAN C4.4A, A SRUCTURAL UPAR HOMOLOGUE
L. Lin* (US), H. Gardsvoll, B. Jacobsen, M. Ploug, M. Huang

PP-WE-226 FIBRINOLYSIS AND ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE (CAD): IS THERE A LINK
A. B. Fernandes, L. M. Lima, M. O. Sousa, V. P. C. Toledo, M. G. Carvalho* (BR)

PP-WE-227 TAFI PLASMA LEVELS ASSESSMENT IN DYSLIPIDEMIC SUBJECTS IN MINAS GERAIS STATE, BRAZIL
M. G. Carvalho* (BR), M. O. Sousa, A. P. Fernandes, C. N. Ferreira

PP-WE-228 FIBRINOLYTIC CAPACITY FOLLOWING A SINGLE MODERATE ETHANOL DOSE, AS MEASURED BY TPA ACT, PAI-1 ACT AND TWO GLOBAL FIBRINOLYTIC CAPACITY ASSAYS
M. Pieters* (ZA), H. H. Vorster, J. C. Jerling, C. S. Venter, R. C. M. Kotze, J. J. Malfliet, D. C. Rijken

PP-WE-229 PLASMIN INHIBITOR AND PAI-1 INHIBITION KINETICS IN FIBRIN CLOTS
M. Silva* (UK), C. Thelwell, K. Kolev, C. Longstaff

PP-WE-230 CHARACTERIZATION OF ANTIBODIES TO TISSUE-TYPE PLASMINOGEN ACTIVATOR (T-PA) IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH THE RECOMBINANT PROTEIN
M. Cugno* (IT), R. Castelli, G. Bisiani, A. Calini, P. M. Mannucci

PP-WE-231 THE INFLUENCE OF ALPHA-2-ANTIPLASMIN POLYMORPHISM ARG6TRP ON FIBRINOLYSIS; THE LEEDS FAMILY STUDY
S. Uitte de Willige* (UK), A. M. Carter, K. F. Standeven, H. Philippou, P. J. Grant, R. A. S. Ariëns

PP-WE-232 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) DURING CARDIOPULMONARY BYPASS
S. J. Davidson* (UK), D. A. Lindsey, L. Tillyer, B. J. Woodhams

PP-WE-233 THE INFLUENCE OF THE DIRECT FACTOR Xa INHIBITOR RIVAROXABAN ON TWO DIFFERENT THROMBIN GENERATION ASSAYS IN PATIENTS WITH THROMBOPHILIA
A. Siegemund* (DE), T. Siegemund, U. Scholz

PP-WE-234 HAEMOSTATIC FACTOR PROFILE DURING ORTHOPAEDIC REPLACEMENT SURGERY IN A HEALTHY POPULATION
C. Altisent* (ES), M. Colomina, J. Massons, C. Fernández, M. Melado, R. Parra

PP-WE-235 COMPARISON OF TWO CHROMOGENIC FVIII ACTIVITY ASSAYS TO A STANDARD CLOT-BASED FVIII ACTIVITY ASSAY
D. L. McGlasson* (US), G. A. Fritsma

PP-WE-236 SUSCEPTIBILITY AND CLINICAL INVOLVEMENT OF 4G/5G POLYMORPHISM OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (4G/5G PAI-1) GENE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). PRELIMINARY RESULTS OF A MULTICENTRE STUDY
G. F. de Larrañaga* (AR), S. Perés Wingeyer, A. Allievi, S. Muñoz, R. Trobo, A. Orden, J. Barreira, A. Álvarez, A. Eimon

PP-WE-237 REDISTRIBUTION OF RECOMBINANT ACTIVATED FACTOR VII INTO PLATELETS AND THE VASCULAR BED: IMPLICATIONS ON HEMOSTATIC MECHANISMS
I. Lopez-Vilchez* (ES), J. Tusell, U. Hedner, C. Altisent, G. Escolar, A. M. Galan

PP-WE-238 PROFIBRINOLYTIC EFFECT OF THROMBIN FORMATION DURING FIBRINOLYSIS
J. R. Ha* (CA), A. Klompas, P. Massicotte, M. Bauman, P. L. Swanson, L. Bajzar

PP-WE-239 APO(A) INCREASES CLOT STABILITY IN TRANSGENIC MICE
J. L. Hoover-Plow* (US), E. Hart, J. Saraniti

PP-WE-240 EFFECT OF IN-VITRO CRYSTALLOID DILUTION ON COAGULATION IN HEALTHY VOLUNTEERS AND PATIENTS WITH A HISTORY OF VENOUS THROMBOSIS OR HEPATIC CIRRHOSIS USING THROMBOELASTOGRAPY (TEG)
J. Kaur* (UK), N. Jones, A. Riddell, C. Melikian, S. Mallett

PP-WE-241 IDENTIFICATION OF HUMAN THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR IN VARIOUS VASCULAR CELL TYPES
J. H. Lin* (CA), M. Garand, S. Schadinger, M. B. Boffa, M. L. Koschinsky

PP-WE-242 DIAGNOSIS OF NONOVERT, PRECLINICAL DIC USING CRITERIA FROM THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HEMOSTASIS
J. Lee* (KR), J. Song

PP-WE-243 PLEIOTROPIC EFFECTS IN THROMBOTIC-RELATED TRAITS USING BIVARIATE VARIANCE COMPONENTS MODELS
A. Buil, Á. Martínez, J. Souto, J. Blangero, L. Rib, M. Borrell, J. Fontcuberta, L. Almasy, J. Soria* (ES)

PP-WE-244 COAGULATION FACTORS DURING LIVER REGENERATION IN MICE
K. Tatsumi* (JP), K. Ohashi, Y. Sakurai, T. Okano, M. Shima

PP-WE-245 REGULATION OF PLASMA THROMBIN GENERATION BY VASCULAR ENDOTHELIAL CELLS
L. Pepler* (CA), P. C. Liaw

PP-WE-246 GENETIC REGULATION OF INFLAMMATION-MEDIATED HAEMOSTASIS ACTIVATION: A FAMILY-BASED APPROACH
L. Iacoviello* (IT), B. Vohnout, F. Gianfagna, A. di Castelnuovo, L. Nanni, E. Napoleone, M. Crescente, A. de Curtis, A. Cutrone, C. Tamburrelli, F. Zurlo, R. Lorenzet, C. Cerletti, M. Arca, G. de Gaetano, M. B. Donati

PP-WE-247 WHOLE BLOOD THROMBOELASTOMETRY PROFILE IN FACTOR V LEIDEN SUBJECTS AFTER IN VITRO ADDITION OF HUMAN ACTIVATED PROTEIN C
L. Spiezia* (IT), D. Bertini, D. Tormene, C. Radu, V. Rossetto, M. Perlati, F. Dalla Valle, P. Simioni

PP-WE-248 WHOLE BLOOD THROMBOELASTOMETRY IN HUMAN AND CYNOMOLGUS MONKEYS
L. Spiezia* (IT), D. Bertini, M. Boldrin, S. Gavasso, C. Radu, P. Zerbinati, C. Bulato, E. Ancona, E. Cozzi, P. Simioni

PP-WE-249 TAFI-DEPENDENT INHIBITION OF FIBRINOLYSIS BY PLATELETS EVALUATED IN WHOLE BLOOD BY THROMBOELASTOGRAPHY
M. Colucci* (IT), C. Carrieri, R. Galasso, F. Semeraro, C. T. Ammollo, F. Incampo, N. Semeraro

PP-WE-250 ANTI-A2 MONOCLONAL ANTIBODY ENHANCING THROMBIN (AND FACTOR Xa)CATALYZED FACTOR VIII ACTIVITY
M. Takeyama* (JP), K. Nogami, T. Soeda, K. Ogiwara, K. Nishiya, M. Shima

PP-WE-251 CYP2C9 GENOTYPES AND RESPONSE TO WARFARIN DURING INITIAL ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION
M. Bedencic* (SI), E. Zemljic, M. Bozic, P. Peternel, M. Stegnar

PP-WE-252 ESTIMATION OF THROMBIN PRODUCTION IN DIFFERENT SUBJECTS
M. Makris* (GR), P. Makris

PP-WE-253 TASK-ORIENTED MODULAR ANALYSIS OF THE BLOOD COAGULATION NETWORK: THE ROLE OF FACTOR V FEEDBACK ACTIVATION IN TRIGGERING CLOT FORMATION
M. A. Panteleev* (RU), A. N. Balandina, M. V. Ovanesov, E. N. Lipets, F. I. Ataullakhanov

PP-WE-254 IMPORTANCE OF LIFELONG ORAL ANTICOAGULANT THERAPY IN ADOLESCENT WITH CONGENITAL THROMBOPHILLIA
M. Jovic* (RS), D. Redzic, O. Serbic, D. Aleksic, D. Djokic

PP-WE-255 A NOVEL FLUOROMETRIC ASSAY OF SIMULTANEOUS THROMBIN AND PLASMIN GENERATION DETECTS ABNORMAL COAGULATION AND FIBRINOLYSIS IN PLASMA
M. L. Grunzke* (US), N. A. Goldenberg, W. E. Hathaway, L. J. Jacobson, C. G. Bombardier, H. A. Hathaway, M. J. Manco-Johnson

PP-WE-256 SYNERGY BETWEEN PHOSPHATIDYLSERINE AND OTHER PHOSPHOLIPIDS IN BLOOD COAGULATION
N. Tavoosi* (US), R. L. Davis-Harrison, J. H. Morrrissey

PP-WE-257 EVALUATION OF SOME HEMOSTATIC PARAMETERS IN PATIENTS WITH END-STAGE RENAL DISEASE: RELATION TO DYSLIPIDEMIA AND HEMODIALYSIS THERAPY
N. K. H. A. Y. R. A. T. Abousamra, T. S. Selim, N. K. Abousamra* (EG), S. M. Elshaarawy

PP-WE-258 PLASMA FACTOR XIIIA LEVELS ARE NOT MAINTAINED BY CIRCULATING PLATELETS DURING THEIR LIFETIME
P. A. Cordell* (UK), B. T. Kile, P. J. Grant, R. J. Pease

PP-WE-259 THE EFFECT OF BLOOD COAGULATION FACTOR XIII ON FIBRIN CLOT STRUCTURE AND FUNCTION
E. L. Smith, R. H. Abou-Saleh, S. D. Connell, K. F. Standeven, P. J. Grant, H. Philippou, R. A. S. Ariëns* (UK)

PP-WE-260 NEW ROLE OF PLATELETS IN INDUCING FIBRIN FORMATION UNDER FLOW
S. E. M. Schols* (NL), M. A. Berny, J. M. E. M. Cosemans, K. Gilio, M. A. H. Feijge, H. Deckmyn, J. W. M. Heemskerk

PP-WE-261 FIBRINOKINETIC DEFICIT IN CHRONIC KIDNEY DISEASE AND END STAGE RENAL DISEASE PATIENTS CONTRIBUTES TO THE HEMOSTATIC ABNORMALITIES
V. Bansal* (US), C. Adiguzel, J. Cunanan, D. Hoppensteadt, O. Iqbal, J. Fareed

PP-WE-262 IN VIVO NEUTRALIZATION OF HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN BY A NOVEL SALICYLAMIDE DERIVATIVE
J. Kuziej, E. Litinas, W. P. Jeske* (US), D. Hoppensteadt, J. M. Walenga, J. Fareed

PP-WE-263 PLASMA LEVELS OF VEGF, PLGF AND SDF-1 ARE DIFFERENTLY MODULATED DURING THE ANTIPHOSPHOLIPID SYNDROME
D. M. Smadja* (FR), P. Gaussem, A. Fischer, J. Emmerich, L. Darnige

PP-WE-264 AUTOANTIBODIES AGAINST THE FIBRINOLYTIC RECEPTOR, ANNEXIN A2, IN CEREBRAL VENOUS THROMBOSIS
G. N. Cesarman-Maus* (MX), F. Barinagarrementería, R. Villa, E. García-Latorre, E. Reyes, K. A. Hajjar, C. Cantu-Brito

PP-WE-265 CLINICAL MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME IN OBSTETRIC PRACTICE
J. Khizroeva* (RU), A. A. D. Makatsaria

PP-WE-266 ANTICARDIOLIPIN ANTIBODIES AND LUPUS ANTICOAGULANT IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS - THE NORTH INDIAN EXPERIENCE
J. Ahluwalia* (IN), S. Singh, S. Naseem, D. Suri

PP-WE-267 CLINICAL PERFORMANCE OF NEW AND QUANTITATIVE ASSAYS FOR THE DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME (APS) ON A FULLY AUTOMATED, CHEMILUMINESCENT ANALYZER
J. Serra* (ES), R. G. Barry, K. A. Morin, C. V. Manion, J. Musial, J. Arnout, M. van Russelt, P. de Moerloose, G. Reber, N. Ruiz, J. Puig

PP-WE-268 CALIBRATED AUTOMATED THROMBOGRAPHY IN QUANTITATION OF LUPUS ANTICOAGULANTS IN THE DIAGNOSIS OF THE ANTIPHOSPHOLIPID SYNDROME
K. M. J. Devreese* (BE), K. Peerlinck, M. F. Hoylaerts

PP-WE-269 THE P38 MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) PATHWAY MEDIATES THE INDUCTION OF TISSUE FACTOR AND ADHESION MOLECULE EXPRESSIONS ON ENDOTHELIAL CELLS
K. Oku* (JP), T. Atsumi, O. Amengual, E. Miyamoto, Y. Fujieda, K. Otomo, M. Kato, H. Kataoka, T. Horita, S. Yasuda, T. Koike

PP-WE-270 ANALYTICAL PERFORMANCE OF NEW AND QUANTITATIVE ASSAYS FOR THE DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME ON A FULLY AUTOMATED, CHEMILUMINESCENT ANALYZER
K. A. Morin* (US), R. G. Barry, J. F. Guasch, N. Ruiz, J. Puig, J. Musial, J. Arnout, G. Reber, P. de Moerloose

PP-WE-271 PREDICTIVE VALUE OF THE ANTIPHOSPHOLIPID SCORE (APL-S) FOR THROMBOTIC EVENTS IN PATIENTS WITH AUTOIMMUNE DISEASES
K. Otomo* (JP), T. Atsumi, Y. Fujieda, M. Kato, E. Miyamoto, K. Oku, O. Amengual, H. Kataoka, T. Horita, S. Yasuda, T. Koike

PP-WE-272 RELAPSING CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME ASSOCIATED WITH EARLY ONSET HELLP SYNDROME AND LIVER INFARCTIONS
L. Schliamser* (IL), R. Gonen, M. Carlebach, E. Schiff, D. Attias

PP-WE-273 THE EFFECT OF LUPUS ANTI-COAGULANTS ON ANTI-COAGULANT THERAPY MONITORING
L. Slavik* (CZ), J. Ulehlova, V. Krcova, A. Hlusi, J. Prochazkova

PP-WE-274 DRUG-INDUCED ANTIPHOSPHOLIPID ANTIBODY SYNDROME - TIME TO RESOLUTION
M. Kennedy* (US), J. S. Dlott

PP-WE-275 MONOCLONAL IGM PARAPROTEIN WITH LUPUS ANTICOAGULANT ACTIVITY – INFLUENCE ON COAGULATION TESTING
M. Milos* (HR), D. Coen Herak, D. Matisic, R. Zadro

PP-WE-276 CLINICAL AND LABORATORY PICTURE OF APS IN A NATIONAL REGISTRY
M. Puurunen* Finland, P. Makkonen, P. Mustonen

PP-WE-277 SIGNIFICANCE OF DELTA TIME VALUE IN THE LA BY HEXAGONAL ASSAY FOR ANTIPHOSPHOLIPID SYNDROME
M. Samonte* (US), O. Tcherniantchouk

PP-WE-278 COMBINED ANTIPLATELET AGENTS MIGHT HELP PREVENT ARTERIAL THROMBOSES IN ANTIPHOSPHOLIPID SYNDROME
M. Yamazaki* (JP), Y. Kadohira, M. Maekawa, T. Hayashi, E. Morishita, H. Asakura, S. Nakao

PP-WE-279 A SERIOUS PROBLEM IN NEW REAGENT LOTS OF BETA(2)- GLYCOPROTEIN I IGG ASSAY
K. Javela, P. Mustonen* Finland

PP-WE-280 SUCCESSFUL TREATMENT OF A CASE OF CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME WITH AUTOLOGOUS BONE MARROW TRANSPLANTATION
T. M. Owaidah* (SA), F. Al Mohareeb, A. Al Harthi, H. Al Zahrani

PP-WE-281 THE AVAIL ME PROJECT: A FIRST REGIONAL EVALUATION OF VENOUS THROMBOEMBOLISM (VTE) RISK AND PROPHYLAXIS PRACTICE
A. Taher* (LB), P. Salameh, G. Dabar, M. Waked, G. Chaar, M. Itani, E. Elias, R. Abdelkarim, A. Alfahim, S. Haggag, N. Shahrour, A. Khoury, M. Aghili, A. Aldeshev, M. Begaliyev, T. Sultanaliev, S. Tuganbekova, A. Vasheghani, R. Vardosanidze, T. Charkviani, J. Aoun

PP-WE-282 THROMBOPHILIA SCREENING IN THE ACUTE PHASE OF DEEP VENOUS THROMBOSIS
A. B. Münster* (DK), J. J. Sidelmann, J. Gram

PP-WE-283 TRANSTHORACIC ECHOCARDIOGRAPHY IN PATIENTS WITH A FIRST EPISODE OF PULMONARY EMBOLISM (PE) FOR THE DETECTION OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTPH)
D. Poli* (IT), E. Antonucci, E. Grifoni, G. Ciuti, M. Miniati, G. Gensini, D. Prisco, R. Abbate, C. Arcangeli

PP-WE-284 DEMOGRAPHIC FEATURES, FUNCTIONAL STATUS AND OUTCOMES OF A LARGE SAMPLE OF PATIENTS DIAGNOSED WITH PULMONARY EMBOLISM IN EMERGENCY DEPARTMENTS IN THE UNITED STATES
J. Hernandez* (US), C. V. Pollack, J. A. Kline, B. Hiestand, D. Slattery, D. Schrieber, R. Pendleton

PP-WE-285 INHERITED THROMBOPHILIA IN NORMAL SAUDI ARABIAN AND THOSE WITH VENOUS THROMBOSIS-THE SAUDI THROMBOSIS AND FAMILIAL TROMBOPHILIA (S TAFT) REGISTRY
J. Saour* (SA), A. Sheereen, T. Saour, M. Shoukri, L. Mammo

PP-WE-286 DOES THE CLINICAL PRESENTATION OF VENOUS THROMBOEMBOLISM PREDICT THE RISK FOR AND TYPE OF THROMBOSIS RECURRENCE
J. Douketis* (CA), A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto

PP-WE-287 SUPERFICIAL THROMBOPHLEBITIS – WHICH CASES ARE MORE RISKY
J. Hirmerova* (CZ), J. Seidlerova, I. Subrt

PP-WE-288 RIGHT ATRIAL THROMBOSIS IN INFANTS AND CHILDREN: LITERATURE REVIEW FROM 1981 TO 2008
J. Y. K. Yang* (CA), S. Williams, L. R. Brandao, A. K. C. Chan

PP-WE-289 THE ROLE OF P4-P3’ RESIDUES IN FACILITATING ACTIVATED PROTEIN C CLEAVAGE OF THE FACTOR VIIIa A1 DOMAIN
J. P. Deangelis* (US), F. Varfaj, H. Wakabayashi, P. J. Fay

PP-WE-290 ROLE OF P16INK4A-MEDIATED CELLULAR SENESCENCE IN IDIOPATHIC, AGERELATED VENOUS THROMBOSIS
J. Cardenas* (US), N. Sharpless, H. Whinna, F. Church

PP-WE-291 SCREENING PATIENTS WITH FACTOR V LEIDEN MUTATION AND PROTEIN S DEFICIENCY AND PROTEIN C DEFICIENCY BY MEASURING THROMBIN GENERATION
J. R. Wu* (US), B. Bai, T. S. Smith

PP-WE-292 BASAL AND LIPOPOLYSACCHARIDE-STIMULATED MONONUCLEAR CELL TISSUE FACTOR PROCOAGULANT ACTIVITY IN PATIENTS WITH PRIOR VENOUS THROMBOEMBOLISM
A. Xue, J. A. Heit* (US), R. Miller, J. Larson, T. M. Petterson, W. G. Owen

PP-WE-293 RELATIONSHIP BETWEEN THE PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) 4G/5G POLYMORPHISM AND CEREBRAL VENOUS THROMBOSIS (CVT). ANOTHER BRICK IN THE WALL
J. M. Ceresetto* (AR), C. Duboscq, C. Doti, F. Bottaro, O. Rabinovich, C. Shanley, G. Stemmelin, E. Bullorsky

PP-WE-294 MOLECULAR CHANGES IN VWF AND ADAMTS13 GENES AND THEIR CORRELATION WITH PLASMA LEVELS OF FVIII AND VWF IN PATIENTS WITH DEEP VENOUS THROMBOSIS
L. F. Bittar, L. H. Siqueira, E. V. de Paula, F. L. A. Orsi, J. M. Annichino-Bizzacchi* (BR)

PP-WE-295 INCREASED ACTIVITY OF COAGULATION FACTORS FVII AND FIX ASSOCIATED WITH RECURRENT THROMBOSIS
T. M. Melo, F. A. Orsi, E. V. de Paula, M. C. Ozelo, J. M. Annichino-Bizzacchi* (BR)

PP-WE-296 THE FACTOR VIII D1241E POLYMORPHISM, LEVELS OF FACTOR VIII AND RISK OF DEEP VENOUS THROMBOSIS IN A BRAZILIAN POPULATION
T. B. T. Mello, L. H. S. Siqueira, S. A. L. Montavão, D. S. P. Paixão, J. M. Annichino-Bizzacchi* (BR)

PP-WE-297 ANTITHROMBIN (AT) DEFICIENCY: EFFECT OF PERIOPERATIVE THROMBOPROPHYLACTIC APPROACH ON VENOUS THROMBOEMBOLIC EVENT (VTE) RATE
T. Sooriyakumar, S. Bretherton, J. K. Phillips* (NZ)

PP-WE-298 A PROSPECTIVE STUDY OF QUANTITATIVE D-DIMER AND ENDOGENOUS THROMBIN POTENTIAL MEASUREMENTS IN INDIVIDUALS STOPPING ORAL ANTICOAGULANTS FOR ACUTE VENOUS THROMBOEMBOLISM; ROLE IN PREDICTING RISK OF RECURRENT THROMBOTIC EVENTS
S. P. Green, E. Hynes, K. Knaggs, J. Hanley, P. Kesteven, K. L. Talks* (UK)

PP-WE-299 USE OF CALIBRATED AUTOMATED THROMBOGRAPHY TO DETECT HYPERCOAGULABILITY
K. R. Machlus* (US), E. A. Colby, J. R. Wu, G. G. Koch, N. S. Key, A. S. Wolberg

PP-WE-300 BLEEDING COMPLICATIONS WITH PHARMACOLOGICAL PROPHYLAXIS FOLLOWING GYNAECOLOGICAL ONCOLOGY SURGERY
K. Hitos* (AU), G. V. Wain, J. P. Fletcher

PP-WE-301 VENOUS THROMBOEMBOLISM PROPHYLAXIS FOLLOWING LAPAROSCOPIC SURGERY
K. Hitos* (AU), J. P. Fletcher

PP-WE-302 THERE IS NO INCREASE IN THROMBIN GENERATION IN PATIENTS WITH IDIOPATHIC INTRACRANIAL HYPERTENSION
K. Hickey* (UK), S. Dhungana, B. Sharrack, P. C. Cooper, M. Makris

PP-WE-303 THE EFFECT OF AGEING ON VENOUS VALVES
K. van Langevelde* (NL), A. ?rámek, A. de Roos, J. H. C. Reiber, F. R. Rosendaal

PP-WE-304 PHYSICAL ACTIVITY AND RISK OF VENOUS THROMBOEMBOLISM -THE TROMSO STUDY
K. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J. Hansen

PP-WE-305 ANTHROPOMETRIC MEASURES OF OBESITY AND RISK OF VTE - THE TROMSO STUDY
K. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J. Hansen

PP-WE-306 ELEVATED FACTOR IX LEVELS AS A RISK FACTOR FOR ARTERIAL AND VENOUS THROMBOSIS
K. J. Smock* (US), R. A. Crist, K. K. Murphy, A. R. Wilson, G. M. Rodgers

PP-WE-307 ABDOMINAL VEIN THROMBOSIS AS THE FIRST CLINICAL FEATURE OF MYELOPROLIFERATIVE SYNDROME
K. M. Zawilska* (PL), M. M. Jamrozek-Jedlinska, A. M. Grzywacz

PP-WE-308 INHERITED THROMBOPHILIA IN PATIENTS WITH THROMBOEMBOLIC DISEASE
L. Lokar* (SI), V. Urlep ?alinoviæ, B. Bizjak, B. Majcen Vivod, I. Maraèiè, E. Kava?

PP-WE-309 RISK OF RECURRENT VENOUS THROMBOEMBOLISM – EFFECT OF AGE
L. Eischer* (AT), S. Eichinger, P. A. Kyrle

PP-WE-310 ROLE OF GENETIC MUTATIONS IN VASCULAR ACCESS THROMBOSIS AMONG HEMODIALYSIS PATIENTS
D. R. A. Rios, D. A. Guimarães, K. B. Gomes, A. P. Fernandes, D. Reis, M. G. Carvalho, L. M. S. Dusse* (BR)

PP-WE-311 OBESITY, POOR MUSCLE STRENGTH AND THE RISK OF VENOUS THROMBOEMBOLISM IN OLDER PERSONS: THE INCHIANTI STUDY
M. di Nisio* (IT), A. di Iorio, E. Porreca, M. Abate, S. Bandinelli, J. Guralnik, R. Molino-Lova, F. Cuccurullo, L. Ferrucci

PP-WE-312 RISK-ASSESSMENT OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS: PRELIMINARY RESULTS FROM A LARGE PROSPECTIVE STUDY
M. Debastos* (BR), J. Caiafa, T. Bogutchi, S. Barreto, S. Rezende

PP-WE-313 INCIDENCE OF CARDIOVASCULAR EVENTS AFTER VENOUS THROMBOEMBOLISM. A SYSTEMATIC REVIEW AND META-ANALYSIS
M. C. Vedovati* (IT), C. Becattini, W. Ageno, F. Dentali, G. Agnelli

PP-WE-314 RETINAL VEIN THROMBOSIS (RVO) AND THROMBOPHILIA
M. S. Bellia* (GR), A. J. Gafou, E. Nomikou, V. Tsevrenis, C. Zafiri, G. Apergis, G. Theodosiadis

PP-WE-315 ANTHROPOMETRY AND VENOUS THROMBOEMBOLISM: A DANISH FOLLOW-UP STUDY
M. T. Severinsen* (DK), S. R. Kristensen, S. P. Johnsen, K. Overvad

PP-WE-316 PREVALENCE OF THROMBOPHILIA IN A COHORT OF 2607 WOMEN: IMPACT OF THE CALF OR PROXIMAL LOCALIZATION OF DEEP VEIN THROMBOSIS
M. Horellou* (FR), J. Conard, V. Olié, C. Flaujac, M. Fontenay, G. Plu-Bureau

PP-WE-317 N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE CORRELATES WITH THE PERCENTAGE OF PULMONARY VASCULAR OBSTRUCTION IN PATIENTS WITH ACUTE PULMONARY EMBOLISM
M. J. Agterof* (NL), R. E. G. Schutgens, J. F. Verzijlbergen, M. M. C. van Buul, E. A. M. Tromp, M. H. Prins, D. H. Biesma

PP-WE-318 RISK STRATIFICATION OF PATIENTS WITH PULMONARY EMBOLISM BASED ON PULSE RATE AND D-DIMER CONCENTRATION
M. J. Agterof* (NL), E. R. van Bladel, R. E. G. Schutgens, R. J. Snijder, E. A. M. Tromp, M. H. Prins, D. H. Biesma

PP-WE-319 A CASE OF SEVERE INHERITED HYPERHOMOCYSTEINEMIA IN A YOUNG MALE HAVING VENOUS THROMBOEMBOLISM AND CLAUDICATION SUCCESSFULLY TREATED WITH VITAMIN B6 AND B9
M. Andersen* (DK), J. Dalsgaard, S. Stender

PP-WE-320 THE METABOLIC SYNDROME AND THE RISK OF IDIOPATHIC VENOUS THROMBOEMBOLISM
M. N. D. di Minno* (IT), A. Guida, A. Tufano, A. Coppola, A. M. de Gregorio, M. di Capua, E. Cimino, A. M. Cerbone, G. di Minno

PP-WE-321 LACK OF CHANGE IN INSULIN LEVELS AS A BIOLOGICAL MARKER OF PAI-1 LOWERING IN 60 GROWTH HORMONE (GH) DEFICIENT ADULTS ON RECOMBINANT HUMAN GH (R-HGH) REPLACEMENT THERAPY: A PROSPECTIVE STUDY
M. N. D. di Minno* (IT), V. Palmieri, G. Lombardi, S. Pezzullo, F. Cirillo, A. Meola, C. di Somma, P. Beck-Peccoz, G. di Minno

PP-WE-322 SAFETY OF VITAMIN K ANTAGONISTS IN PULMONARY ARTERIAL HYPERTENSION
M. V. Huisman* (NL), T. A. Hazenoot, I. R. Henkens, H. W. Vliegen, A. Boonstra, P. E. Postmus, A. Vonk Noordegraaf

PP-WE-323 DECREASED HEME OXYGENASE-1 EXPRESSION IN PATIENTS WITH PULMONARY HYPERTENSION FOLLOWING PULMONARY EMBOLISM
M. R. Marchick* (US), J. A. Kline

PP-WE-324 A COMPARISON OF THE PREVALENCE OF HEREDITARY NATURAL ANTICOAGULANT PATHWAY DEFECTS BETWEEN PATIENTS WITH DVT, PE AND THROMBOSIS AT UNUSUAL SITES
M. Ahmadinejad* (IR), D. Bashash, T. Ahmadinejad, S. Zolfaghari, M. Tabatabaii, K. Atarodi, L. Seyed Mortaz, S. Baluch

PP-WE-325 CORONARY ARTERY DISEASE AND-OR CEREBRAL NON-FATAL ISCHEMIC STROKE FOLLOWING RETINAL VEIN OCCLUSION: A 8-YRS FOLLOW-UP
M. di Capua* (IT), M. N. D. di Minno, A. Guida, A. M. de Gregorio, C. Cuccaro, M. Loffredo, A. Tufano, E. Ciminno, A. Coppola, A. M. Cerbone, G. di Minno

PP-WE-326 STATIN USE IN PATIENTS WITH NEPHROTIC SYNDROME IS ASSOCIATED WITH RISK REDUCTION OF VENOUS THROMBOEMBOLISM
M. Resh* (NL), B. Mahmoodi, G. Navis, N. Veeger, W. Lijfering, J. van der Meer

PP-WE-327 ENOS POLYMORPHISMS MAY BE A RISK FACTOR FOR DEEP VEIN THROMBOSIS IN INDIAN ASIAN POPULATION
M. S. Akhter* (IN), A. Biswas, R. Ranjan, A. Meena, A. Sharma, S. Kumar, R. Saxena

PP-WE-328 EPIDEMIOLOGY OF AND RISK FACTORS FOR UPPER EXTREMITY VENOUS THROMBOSIS IN THE POPULATION-BASED MALMO TROMBOPHILIA STUDY, (MATS)
N. Isma* (SE), P. J. Svensson, A. Gottsäter, B. Lindblad

PP-WE-329 PHYSICIAN COMPLIANCE WITH ADVANCED NON-INTERRUPTIVE ELECTRONIC ALERTS FOR PREVENTING VENOUS THROMBOEMBOLISM AMONG HOSPITALIZED MEDICAL PATIENTS
N. Kucher* (CH), M. Puck, D. Spirk, G. Bucklar, E. Eschmann, T. F. Lüscher

PP-WE-330 ANTHROPOMETRIC AND HAEMOSTATIC CARDIOVASCULAR RISK IN YOUNG NIGERIAN SEMI VEGETARIANS
O. A. Awodu* (NG), A. A. Adeyemi, O. A. Omolade, Y. O. Makinde, O. I. Ajayi, A. A. Famodu

PP-WE-332 RISK ASSESSMENT AND MANIFESTATION OF VENOUS THROMBOSIS (VT) IN PREGNANCY AMONG CARRIERS OF THE FACTOR V LEIDEN AND THE PROTHROMBIN GENE 20210GA MUTATIONS – A POPULATION-BASED CASECONTROL STUDY
A. F. Jacobsen, F. E. Skjeldestad, A. Bergrem, P. M. Sandset* (NO)

PP-WE-333 PERFORMANCE OF THE HEMOSIL THROMBOPATH ASSAY IN THE SCREENING FOR PROTEIN C PATHWAY ABNORMALITIES. PRELIMINARY RESULTS IN 352 UNSELECTED PATIENTS WITH A HISTORY OF THROMBOSIS
P. A. Toulon* (FR), I. Martin Toutain, A. Ankri

PP-WE-334 FACTOR V LEIDEN AND THROMBIN GENERATION AND RISK OF RECURRENT THROMBOTIC EPISODES IN A PATIENT COHORT WITH VENOUS THROMBOEMBOLISM. THE LIST STUDY
R. Chaireti, C. Jennersjö, T. L. Lindahl* (SE)

PP-WE-335 HAEMOSTATIC GENE FACTORS AND RISK OF VASCULAR EVENTS IN RUSSIAN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: THE RESULTS OF 4 YEARS FOLLOW-UP
A. L. Komarov* (RU), O. Shakhmatova, D. Rebrikov, I. Kofiady, D. Stambolsky, A. Deev, E. Panchenko

PP-WE-336 THE HEMOSTATIC SYSTEM IN PATIENTS WITH TYPE 2 DIABETES WITH AND WITHOUT CARDIOVASCULAR DISEASE
C. J. N. Verkleij* (NL), V. E. A. Gerdes, R. de Bruijn, J. C. M. Meijers, P. F. Marx

PP-WE-337 HAEMOSTATIC AND INFLAMMATORY BIOMARKERS IN CHRONIC HEART FAILURE
E. G. Oganova* (BY), S. F. Zolotukhina, S. M. Komissarova, O. A. Petruk

PP-WE-338 AGE IS MORE IMPORTANT TO PREDICT CAROTID STENOSIS AMENABLE OF SURGICAL CORRECTION THAN FOCAL NEUROLOGICAL SYMPTOMS
F. Verlato* (IT), G. Verlato, M. Marzolo, G. Camporese, F. Rosso, F. Busonera, M. Nardi, G. Andreozzi

PP-WE-339 INCREASED ACTIVE VON WILLEBRAND FACTOR IN YOUNG WOMEN WITH ACUTE MYOCARDIAL INFARCTION
F. Peyvandi* (IT), M. J. Hollestelle, R. Palla, M. F. M. de Rooij, H. Feys, D. Ardissino, P. Merlini, P. J. Lenting, P. M. Mannucci

PP-WE-340 JAK2V617F MUTATION IN PATIENTS WITH ARTERIAL THROMBOSIS IN THE ABSENCE OF OVERT MYELOPROLIFERATIVE DISEASE
F. Dentali* (IT), A. Squizzato, L. Appio, L. Brivio, W. Ageno

PP-WE-341 RISK OF ARTERIAL CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE PULMONARY EMBOLISM
F. A. Klok* (NL), I. C. M. Mos, L. Broek, J. T. Tamsma, F. R. Rosendaal, A. de Roos, M. V. Huisman

PP-WE-342 STATIN THERAPY MAY HAVE BEEN INVOLVED IN THE REDUCTION OF CARDIOVASCULAR EVENTS VIA SUPPRESSION OF ENHANCED THROMBOXANE PRODUCTION
H. Omori* (JP), K. Murasaki, Y. Uetsuka, N. Hagiwara

PP-WE-343 PREVALENCE OF C677T AND A1298C POLYMORPHISMS IN METHYLENETETRAHYDROFOLATE REDUCTASE GENE IN PATIENTS WITH CORONARY HEART DISEASE
S. Park, H. Chi* (KR), S. Min, S. Jang, C. Park

PP-WE-344 PREDICTION OF CARDIOVASCULAR EVENTS BY MMP-9 IN ELDERLY MEN
T. Weiss, I. Seljeflot* (NO), E. B. Furenes, H. Arnesen

PP-WE-345 LOCAL PROCOAGULANT STATE IN THE LEFT ATRIUM OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
I. V. Hrachovinová* (CZ), P. ?ulc, M. Zemanova, V. Melenovsk?, D. Wichterle, G. Y. H. Lip, J. Kautzner

PP-WE-346 VON WILLEBRAND FACTOR DOES NOT PREDICT OUTCOME IN UNSTABLE ANGINA
J. E. van Loon* (NL), J. W. Jukema, F. W. G. Leebeek, M. P. M. de Maat

PP-WE-347 FREQUENCY OF THE POLYMORPHISM -1131T> C IN APOLIPOPROTEIN A5 (APOA5) GENE IN SUBJECTS IN MINAS GERAIS STATE - BRAZIL
K. B. Gomes* (BR), A. P. Fernandes, N. G. Cruz, F. F. Coelho, I. R. Santos, K. F. Rodrigues, P. S. Pinheiro, D. A. Guimarães, M. O. Sousa

PP-WE-348 A POSSIBLE MECHANISM OF FASTER ONSET OF PRASUGREL - THE INTESTINE AS AN IMPORTANT CONTRIBUTOR TO THE ACTIVE METABOLITE FORMATION IN VIVO
K. Hagihara* (JP), M. Kazui, H. Ikenaga, T. Nanba, K. Fusegawa, A. Kurihara, O. Okazaki

PP-WE-349 COULD D-DIMER IN THE TYPE 2 DIABETIC PATIENTS BE A MARKER OF THE MACROVASCULAR COMPLICATIONS
K. Yokoyama* (JP), Y. Tsukada, Y. Matsubara, T. Kawai, Y. Oikawa, A. Shimada, H. Itoh, M. Murata, Y. Ikeda

PP-WE-350 FACTOR XIII A SUBUNIT VAL34LEU POLYMORPHISM IN PATIENTS SURVIVING OR NOT SURVIVING ISCHEMIC STROKE
L. Muszbek* (HU), A. H. Shemirani, B. Antalfi, E. Pongrácz, R. Ádány

PP-WE-351 LOOKING FOR EARLY SIGNS OF ATHEROSCLEROTIC ALTERATIONS IN CARRIERS OF INHERITED THROMBOPHILIA
L. Valdre* (IT), C. Legnani, B. Cosmi, M. Cini, E. Favaretto, G. Palareti

PP-WE-352 DETERMINANTS OF THROMBIN GENERATION IN ACUTE MYOCARDIAL INFARCTION
M. Smid* (NL), A. W. J. H. Dielis, R. van Oerle, J. W. P. Govers-Riemslag, H. M. H. Spronk, K. Hamulyák, M. Prins, J. Rosing, J. Waltenberger, H. ten Cate

PP-WE-353 REDUCED THROMBIN GENERATION IS ASSOCIATED WITH MYOCARDIAL INFARCTION IN THE GLASGOW MYOCARDIAL INFARCTION STUDY (GLAMIS)
M. Smid* (NL), M. Woodward, R. van Oerle, H. M. H. Spronk, A. Rumley, H. ten Cate, G. Lowe

PP-WE-354 PLASMA GLUTATHIONE PEROXIDASE (GPX-3) AND APOLIPOPROTEIN (A) (APOA) IN YOUNG PATIENTS WITH NON-EMBOLIC ISCHEMIC STROKE (IS): A SUB-GROUP ANALYSIS
M. F. Alberto* (AR), P. Casais, L. Jones, G. Campregher, S. Meschengieser, M. A. Lazzari

PP-WE-355 ENDOTHELIAL CELL ACTIVATION MEASURED BY VON WILLEBRAND FACTOR PROPEPTIDE IN ISCHEMIC STROKE PATIENTS
M. C. van Schie* (NL), M. P. M. de Maat, A. A. Hyseni, D. W. J. Dippel, P. J. Lenting, P. G. de Groot, F. W. G. Leebeek, M. J. Hollestelle

PP-WE-356 PLATELET BEHAVIOUR IN PATIENTS WITH DRUG-ELUTING STENTS AFTER THIENOPYRIDINE TREATMENT DISCONTINUATION
M. Camera* (IT), D. Trabattoni, D. Villa, A. Bartorelli, P. Bogani, M. Brambilla, E. Tremoli

PP-WE-357 INCREASED INNATE AND ADAPTIVE IMMUNE CELL CONCENTRATIONS IN BLOOD PREDICT AN INCREASED CARDIOVASCULAR DISEASE INCIDENCE
M. Roest* (NL), H. B. Bueno-De-Mesquita

PP-WE-358 PLASMA FACTOR AND INHIBITOR COMPOSITION CONTRIBUTES TO THROMBIN GENERATION DYNAMICS IN ACUTE CEREBROVASCULAR EVENTS
M. Gissel* (US), A. Undas, A. Slowik, K. G. Mann, K. Brummel-Ziedins

PP-WE-359 THROMBOPHILIC RISK FACTORS AND OUTCOME IN PATIENTS UNDERGOING ENDOVASCULAR INTERVENTION FOR PERIPHERAL ARTERIAL DISEASE
M. Sartori* (IT), E. Conti, E. Favaretto, C. Legnani, G. Guazzaloca, L. Valdre’, C. Pili, G. Palareti

PP-WE-360 MAJOR BLEEDING EVENTS IN STABLE OUTPATIENTS WITH CORONARY, CEREBROVASCULAR OR PERIPHERAL ARTERY DISEASE. FINDINGS FROM THE FRENA REGISTRY
T. Gadelha, J. Bisbe, J. Toril, J. N. Alcalá Pedrajas, C. Sanclemente, T. Pascual, M. Manuel* (ES)

PP-WE-361 MOLECULAR GENETICS ANALYSIS IN CORONARY ARTERY DISEASE
O. A. Smirnova* (RU), V. M. Shmeleva, S. I. Kapustin, N. A. Klenkova, M. N. Blinov, L. P. Papayan

PP-WE-362 FACTOR XIa AND TISSUE FACTOR ACTIVITY IN PATIENTS WITH CARDIOVASCULAR AND INFLAMMATORY DISEASES
S. Butenas* (US), A. Undas, M. Gissel, K. G. Mann

PP-WE-363 FONDAPARINOX FOR A PREGNANT WOMAN WITH DEEP VEIN THROMBOSIS AND HEPARIN ALLERGY
A. M. Almomen* (SA), A. M. Abdel Gader

PP-WE-364 ABO BLOOD GROUP GENOTYPING AND VENOUS THROMBOSIS IN BRAZILIAN WOMEN USING ESTROGEN
M. S. Santos, D. A. M. Guimarães, S. G. Paiva, A. P. Sabino, M. G. Carvalho, D. D. Ribeiro, K. B. Gomes, L. M. S. Dusse, A. P. Fernandes* (BR)

PP-WE-365 LIPIDS AND APOLIPOPROTEINS (APO B/APO A-I RATIO) IN POST-MENOPAUSAL WOMEN UNDER HORMONE REPLACEMENT THERAPY
D. A. M. Guimarães, D. Diniz, K. B. Gomes, M. S. Santos, R. M. Franco, G. S. Teixeira, M. Carvalho, A. Fernandes* (BR), M. O. Sousa

PP-WE-366 SPORADIC MUTATIONS WITHIN THE EXON 8 OF PROTEIN Z ARE SIGNIFICANTLY ASSOCIATED WITH THE OCCURRENCE OF FETAL LOSS
G. Favuzzi, D. Colaizzo, V. de Stefano, E. Rossi, D. Pisanelli, F. Cappucci, T. Za, R. Santacroce, M. Margaglione, E. Grandone* (IT)

PP-WE-367 JAK2 V617F MUTATION IS NOT ASSOCIATED WITH PREGNANCY LOSS: A NESTED CASE-CONTROL STUDY
D. Colaizzo, P. Vergura, G. Favuzzi, G. Vecchione, A. Iannaccone, L. Greco, L. Mazzarelli, P. Martinelli, G. D’ Andrea, M. Margaglione, E. Grandone* (IT)

PP-WE-368 LOCALISATION AND PERIOD OF VENOUS THROMBOSIS OCCURRENCE IN THROMBOPHILIC WOMEN WITH PREGNANCY AND PUERPERIUM RELATED VENOUS THROMBOEMBOLIC DISEASE
G. Mitic* (RS), M. Kovac, L. Povazan, V. Djordjevic, Z. Magic, I. Salatic, N. Antonijevic, A. Novakov Mikic

PP-WE-369 PREDICTION OF ANTI Xa ACTIVITY LEVEL IN PREGNANT WOMEN RECEIVING LOW MOLECULAR WEIGHT HEPARIN USING ARTIFICIAL NEURAL NETWORK AND SUPPORT VECTOR MACHINES
G. Mitic* (RS), M. Scekic, D. Jurisic, L. Povazan, R. Tesic, M. Petkovic, B. Jakovljevic, Z. D. Jelicic

PP-WE-370 REFERENCE RANGES FOR THE DETERMINATION OF D-DIMERS IN PREGNANCY
G. Kappert* (DE), S. Halimeh, H. Rott

PP-WE-371 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) LEVELS, TAFI GENE POLYMORPHISMS AND CLOT LYSIS TIME IN PREGNANT PATIENTS: RELATIONSHIP WITH PREECLAMPSIA AND/OR INTRAUTERINE FETAL GROWTH RESTRICTION
D. Tassies, M. A. Martinez, J. Monteagudo, C. Freire, J. Pijoan, F. Carmona, J. Balasch, J. C. Reverter* (ES)

PP-WE-372 ENDOGENOUS THROMBIN POTENTIAL: PROFILES IN NORMAL PREGNANCY AND PRO-THROMBOTIC PREGNANT WOMEN
E. Hynes, K. Knaggs, S. McCourt, C. Bomken, A. D. Loughney, P. Kesteven, J. P. Hanley* (UK)

PP-WE-373 EFFECT OF GENISTEIN VERSUS OESTROGEN ON HAEMOSTATIC GENE EXPRESSION IN OVARIECTOMISED RATS
L. A. Kelly* (IE), W. Wuttke, J. J. O’Leary, L. A. Norris

PP-WE-374 GESTATIONAL VASCULAR COMPLICATIONS: SCREENING FOR CONGENITAL THROMBOPHILIA
S. Morais, C. Laranjeira, S. Faria, L. Lima, R. Lopes, M. Pereira, L. Moreira, F. Oliveira, E. Valente, A. Cunha, J. Braga, M. Campos* (PT)

PP-WE-375 THROMBOPROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN AFTER CAESAREAN SECTION: A DECISION ANALYSIS
M. Blondon* (CH), M. Righini, A. Perrier, M. Nendaz, F. Boehlen, M. Boulvain, P. de Moerloose

PP-WE-376 ALTERNATIVE ANTICOAGULATION WITH FONDAPARINUX IN PREGNANT PATIENTS WITH HEPARIN-INTOLERANCE
M. Schindewolf* (DE), B. Linnemann, B. Luxembourg, E. Lindhoff-Last

PP-WE-377 PREDICTORS OF CARDIOVASCULAR DISEASE IN PRE-ECLAMPSIA
M. G. Macey* (UK), S. Bevan, S. Alam, L. Verghese, S. G. Agrawal, S. Beski, R. Thuraisingham, P. K. MacCallum

PP-WE-378 THE SIGNIFICANCE OF ENDOTHELIAL MARKERS ACTIVATION IN THE PREDICTION OF SUBSEQUENT DEVELOPMENT OF PREECLAMPSIA
M. Procházka* (CZ), J. Procházková, R. Pilka, L. Slavík, J. Úlehlová, A. Mechurová, O. ?imetka, A. Hlu?í

PP-WE-379 THROMBOPHILIA PRESENCE AMONG WOMEN WITH PREGNANCY-ASSOCIATED COMPLICATIONS: FETAL LOSS OR PREGNANCY RELATED VENOUS THROMBOEMBOLISM
M. Kovac* (RS), G. Mitic, Z. Mikovic, V. Djordjevic, V. Mandic, L. Rakicevic, D. Mikovic, D. Radojkovic

PP-WE-380 HAEMOLYTIC URAEMIC SYNDROME (HUS) WITHIN TWO HOURS POSTPARTUM
M. M. Tea* (AT), R. Kroiss, D. Bikas, T. Wagner

PP-WE-381 VIRAL INFECTIONS, INFLAMMATION, PATHOLOGY OF HEMOSTASIS AND PLACENTAL FAILURE
N. V. Dolgushina* (RU), A. Makatsaria

PP-WE-382 ROLE OF ACTIVATED RECOMBINANT FACTOR VII IN MASSIVE POSTPARTUM HEMORRHAGE
N. Hossain* (PK), T. Shamsi, S. Haider, N. Khan, E. Triche, C. Lockwood, M. Paidas

PP-WE-383 GESTATION AGE SPECIFIC REFERENCE INTERVALS FOR COAGULATION TESTS DURING UNCOMPLICATED PREGNANCY DELIVERY AND EARLY POSTPARTUM PERIOD
P. B. Szecsi* (DK), M. Jørgensen, A. Klajnbard, N. P. Colov, M. R. Andersen, A. Barfoed, K. Haahr, B. Bjørngaard, S. Stender

PP-WE-384 IMMUNOLOGICAL CHARACTERIZATION AND ANALYSIS OF SEQUENCE ALIGNMENT OF THE COAGULATION PROTEINS IN PRIMATES AND PIGS
C. Bulato* (IT), C. Radu, G. Cozza, M. Boldrin, L. Spiezia, S. Gavasso, E. Cozzi, P. Simioni

PP-WE-385 INCREASED ANTITHROMBOTIC AND BLEEDING EFFECTS OF CONTAMINATED HEPARINS; HEMATOLOGICAL IMPLICATIONS
E. Litinas* (US), C. Adiguzel, W. Jeske, D. Hoppensteadt, H. Messmore, J. Walenga, J. Fareed

PP-WE-386 EVALUATION OF BOTH ANTI- AND PRO-THROMBOTIC EFFECTS IN A DOG MODEL OF ARTERIAL THROMBOSIS, MODIFIED FOLTS MODEL
J. Björkman* (SE), A. Bulhak, H. Zachrisson

PP-WE-387 FIBRIN CLOT FORMATION DIFFERS IN THE PRESENCE OF BRANDED AND GENERIC ENOXAPARINS
J. M. Walenga* (US), C. Adiguzel, O. Iqbal, D. Hoppensteadt, J. Cunanan, M. Bakhos

PP-WE-388 BODY DISTRIBUTION OF IDRAPARINUX AND IDRABIOTAPARINUX IN RATS
J. Herault* (FR), F. Hurbin, M. Pasdelou, B. Remandet, M. Trellu

PP-WE-389 THE ROLE OF THE VWF A1 DOMAIN IN MURINE MODELS OF TTP AND HEMOSTASIS
J. Y. Barr* (US), D. G. Motto

PP-WE-390 COMPARISON OF THE ANTITHROMBOTIC AND BLEEDING EFFECTS OF THE DIRECT THROMBIN INHIBITOR, DABIGATRAN, WITH ENOXAPARIN, HEPARIN AND WARFARIN IN RATS
J. van Ryn* (DE), I. Kuritsch, M. Kink-Eiband, H. Priepke, W. Wienen

PP-WE-391 ERYTHROCYTE HEMOLYSIS AND HEMOGLOBIN OXIDATION PROMOTE FERRIC CHLORIDE INDUCED VASCULAR INJURY
K. J. Woollard* (AU), S. Sturgeon, J. Chin-Dusting, H. Salem, S. P. Jackson

PP-WE-392 ANTITHROMBOTIC ACTIVITY OF ORAL HEPARINS IN A PORCINE MODEL
L. M. Hiebert* (CA), T. Ping, S. M. Wice

PP-WE-393 TRANSPORT OF HEPARINS ACROSS RAT GASTRIC MUCOSA: DOES IT DEPEND ON ACTIVE TRANSPORT
B. Moazed, L. M. Hiebert* (CA)

PP-WE-394 WHY DO THROMBI STOP GROWING? - FIBRIN POLYMERIZATION MAY LIMIT CLOT GROWTH
M. Kamocka* (US), Z. Xu, J. Mu, X. Liu, M. Alber, D. Chen, E. D. Rosen

PP-WE-395 FALSE-POSITIVE HIT-ELISA SPECIMENS MAY CONTAIN ANTIBODIES THAT RECOGNIZE NON-SPECIFIC HEPARIN-BOUND CATIONIC PEPTIDES
M. Prechel* (US), V. Escalante, J. M. Walenga

PP-WE-396 ANTITHROMBOTIC PROPERTIES OF S 35972, A NEW ORALLY ACTIVE THROMBIN INHIBITOR
M. O. Vallez* (FR), P. Gloanec, G. de Nanteuil, A. Rupin, T. J. Verbeuren

PP-WE-397 THE PREVENTION OF EXPERIMENTAL THROMBUS FORMATION UNDER THE INFLUENCE OF PRO-GLY-PRO-ARG
M. Grigorjeva* (RU), T. Obergan

PP-WE-398 EFFECTS OF TAK-442, A DIRECT FACTOR Xa INHIBITOR, AND FONDAPARINUX ON PLATELET-ASSOCIATED PROTHROMBINASE IN THE BALLOON INJURED ARTERY OF RATS
N. Konishi, H. Katsuhiko, Y. Imaeda, T. Fujimoto, K. Kubo, M. Kawamura* (US)

PP-WE-399 EFFECTS OF ACTIVATED RECOMBINANT FACTOR VII (RFVIIa) ON COAGULATION PARAMETERS IN HEMORRHAGED ACIDOTIC AND PH CORRECTED SWINE
M. A. Dubick* (US), D. N. Darlington, M. R. Scherer, W. Z. Martini, B. S. Kheirabadi

PP-WE-400 ANTITHROMBOTIC PROFILES OF TAK-442, A NOVEL ORAL FACTOR Xa INHIBITOR, IN VENOUS AND ARTERIAL THROMBOSIS MODELS
N. Konishi* (JP), K. Hiroe, E. Shinozawa, K. Shofuda, K. Matsuda, Y. Imaeda, T. Fujimoto, K. Kubo, M. Kawamura

PP-WE-401 DETECTION OF CANINE COATED PLATELETS BY THREE COLOR FLOW CYTOMETRY
T. Knudsen* (DK), M. Kjalke, M. Tranholm, A. L. Jensen, A. T. Kristensen

PP-WE-402 EFFECTS OF SHORT-TERM GLUCOCORTICOIDS ON VON WILLEBRAND FACTOR IN MICE. PRELIMINARY RESULTS
V. A. Zapata* (AR), A. C. Kempfer, J. H. Paiva Palomino, O. G. Astudillo, H. Costa, M. A. Lazzari, A. Sánchez Luceros

PP-WE-403 A RANDOMIZED, PROSPECTIVE, OPEN-LABEL STUDY ON DISTAL VEIN THROMBOSIS (LOW-MOLECULAR-WEIGHT HEPARIN VERSUS WARFARIN FOR SIX WEEKS): THE TODI STUDY
A. Ghirarduzzi* (IT), G. Camporese, S. Siragusa, D. Imberti, E. Bucherini, F. Landini, W. Ageno, P. Prandoni

PP-WE-404 POOLED ANALYSIS OF FOUR RIVAROXABAN STUDIES: NSAIDS, ASA AND PLATELET INHIBITORS
B. I. Eriksson* (SE), A. G. G. Turpie, M. R. Lassen, A. K. Kakkar, M. Gent

PP-WE-405 A POOLED EFFICACY AND SAFETY ANALYSIS OF THE USE OF ANTITHROMBIN (RECOMBINANT) IN HEREDITARY AT DEFICIENT PATIENTS IN HIGH-RISK SITUATIONS
C. Tait* (UK), M. J. Paidas, J. Frieling

PP-WE-406 LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS) FOR PROPHYLAXIS OF VTE IN PATIENTS WITH SEVERE RENAL INSUFFICIENCY: AN ANALYSIS OF RECENT CLINICAL TRIALS
E. Nutescu* (US), A. C. Spyropoulos

PP-WE-407 BUNGEE JUMPING LEADS TO ACTIVATION OF COAGULATION AND VASCULAR ENDOTHELIUM
E. C. Lowenberg* (NL), D. J. van Westerloo, G. Choi, A. F. de Vos, J. C. M. Meijers, T. van der Poll, M. Levi

PP-WE-408 SMOKING INDUCES AN EPIGENETIC MODIFICATION OF PLATELET SEROTONIN CATABOLISM
F. Rendu* (FR), M. Del Pino, G. Chironi, J. Callebert, K. Peoc’H, A. Simon, J. Launay

PP-WE-409 VENOUS THROMBOEMBOLISM PROPHYLAXIS GUIDELINE IMPLEMENTATION IS IMPROVED BY A DEDICATED NURSE PRACTITIONER IN MEDICAL PATIENTS
H. Gibbs* (AU), J. Fletcher, P. Blombery, R. Collins, T. Glennane

PP-WE-410 FONDAPARINUX 2.5 MG FOR THE TREATMENT OF SYMPTOMATIC, ISOLATED SUPERFICIAL THROMBOPHLEBITIS (ST): PRELIMINARY DATA FROM THE RANDOMIZED PLACEBO-CONTROLLED CALISTO TRIAL (ON BEHALF OF THE CALISTO INVESTIGATORS
H. Décousus* (FR), A. Leizorovicz, P. Prandoni

PP-WE-411 DETERMINATION OF PT-INR BY NEW PORTABLE DEVICE (COAGUCHECK XS)
H. Iwahashi* (JP), T. Tashiro, N. Morishige, K. Tacheuchi, M. Nishimi, Y. Hayashida, N. Ito, G. Kuwahara

PP-WE-412 IMPROVING ANTICOAGULATION CONTROL IN HOSPITALIZED ELDERLY PATIENTS ON WARFARIN
I. Gouin-Thibault* (FR), C. Levy, E. Pautas, J. Cambus, L. Drouet, I. Mahé, C. Bal Dit Sollier, M. Horellou, J. Golmard, V. Siguret

PP-WE-413 NO INTERACTION OF IDRAPARINUX AND ASPIRIN WHEN CO-ADMINISTERED TO HEALTHY SUBJECTS
I. Paty* (FR), M. Trellu

PP-WE-414 COMBINED USE OF D-DIMER AND THE EXHALED CO2/O2 EXCLUDE PULMONARY EMBOLISM
J. A. Kline* (US), D. M. Courtney, C. D. Miller, H. A. Smithline, R. Lanier, M. M. Hogg

PP-WE-415 PHARMACOKINETICS AND SAFETY OF BEMIPARIN AFTER MULTIPLE PROPHYLACTIC AND SINGLE THERAPEUTIC DOSES IN YOUNG AND ELDERLY HEALTHY VOLUNTEERS – NO NEED FOR DOSE ADJUSTMENT
S. Rico, R. M. Antonijoan, J. Martinez-Colomer, M. Borrell, J. Fontcuberta* (ES), M. Monreal, J. Martinez-Gonzalez, M. J. Barbanoj

PP-WE-416 ALX-0081 A NOVEL ANTI-THROMBOTIC: FIRST RESULTS OF A MULTIPLE DOSE PHASE 1 STUDY IN PATIENTS WITH STABLE ANGINA UNDERGOING PCI
J. Holz* (BE), J. Bartunek, E. Barbato, K. Vercruysse, S. Pullan, G. Heyndrickxs

PP-WE-417 ACCURACY AND PRECISION OF INRATIO 2 - A NEW GENERATION OF A POINT OF CARE COAGULOMETER
J. Engelsen* (DK), J. Dalsgaard Nielsen

PP-WE-418 PLATELET COX-2 EXPRESSION IS A STRONG PREDICTOR FOR FUTURE CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
K. M. Murasaki* (JP), H. Omori, A. Kobayashi, Y. Uetsuka, N. Hagiwara

PP-WE-419 DECREASING WARFARIN SENSITIVITY DURING THE FIRST THREE MONTHS AFTER HEART VALVE SURGERY: IMPLICATIONS FOR DOSING
K. Meijer* (CA), Y. Kim, S. Schulman

PP-WE-420 INCREASED LEVELS OF PLATELET-DERIVED MICROPARTICLES IN SEPTIC PATIENTS WITH DIC
K. Kawasugi* (JP), R. Shirasaki, H. Tashiro, N. Shirafuji, C. Shimazu, Y. Miyazawa

PP-WE-421 EFFECTS OF AGE, WEIGHT, GENDER AND RENAL FUNCTION IN A POOLED ANALYSIS OF FOUR RIVAROXABAN STUDIES
K. A. Bauer* (US), A. G. G. Turpie, M. R. Lassen, A. K. Kakkar, B. I. Eriksson, M. Gent

PP-WE-422 POLYUNSATURATED FATTY ACIDS,VITAMIN E, AND COENZYME Q10 IN THERAPY OF METABOLIC SYNDROME
L. V. Lyutova* (RU), V. M. Panchenko, G. S. Simowchenko, A. A. Ershov, V. A. Isaev

PP-WE-423 SINGLE ADMINISTRATION OF IDRABIOTAPARINUX HAS NO EFFECT ON DIGOXIN PHARMACOKINETICS IN HEALTHY SUBJECTS
M. Trellu* (FR), S. Cartot-Cotton, D. Ibghi, I. Paty, G. Sanderink

PP-WE-424 PORTAL VEIN THROMBOSIS MANAGEMENT IN CANDIDATES FOR LIVER TRANSPLANTATION (LT)
M. T. Sartori* (IT), C. Ferronato, P. Boccagni, D. Gasparini, U. Cillo, M. Senzolo

PP-WE-425 CONVENIENCE OF AND SATISFACTION WITH THE NEW LONG-ACTING ANTICOAGULANT IDRAPARINUX (IDRA) VS. VITAMIN K ANTAGONIST (VKA) IN PATIENTS WITH DEEP VENOUS THROMBOSIS (DVT), PULMONARY EMBOLISM (PE) AND ATRIAL FIBRILLATION (AF)
M. H. Prins* (NL), P. Leguet, H. Gilet, B. Arnould

PP-WE-426 LABORATORY MONITORING OF HEPARINEMY
R. Apostolovska* (MK), S. Kostovska, V. Dejanova, V. Neceva, T. Balkanov, S. Atanasova, S. Useini, I. Nikoloska

PP-WE-427 SURVEY OF CURRENT MANAGEMENT OF ISOLATED DISTAL DEEP VEIN THROMBOSIS
N. Blest, R. Fitridge, S. J. McRae* (AU)

 

PP-WE-428 SURVEY ON PHYSICIANS’ ADHERENCE TO DEEP VENOUS THROMBOSIS PROPHYLAXIS GUIDELINES IN A TERTIARY HOSPITAL
G. V. Alemany* (PH), C. C. Budhrani, A. P. Bautista, E. B. Madronio, E. C. Santos

PP-WE-429 BARRIERS TO AND POTENTIAL SOLUTIONS TOWARD OPTIMAL PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS FOR HOSPITALIZED MEDICAL PATIENTS: A SURVEY OF HEALTHCARE PROFESSIONALS
N. S. Lloyd* (CA), J. D. Douketis, J. Cheng, H. J. Schunemann, D. J. Cook, L. Thabane, M. Pai, F. A. Spencer, R. Haynes

PP-WE-430 PATIENTS AT HIGHEST RISK FOR VENOUS THROMBOEMBOLISM ARE NOT RECEIVING SPECIFIC DISCHARGE INSTRUCTIONS WARNING FOR SIGNS AND SYMPTOMS OF VTE: A DOUBLE SETBACK
O. Dabbagh* (US), W. A. Parker, M. A. Philpot, M. B. Keegan, J. P. Bosanquet

PP-WE-431 DEVELOPMENT OF FACTOR V LEIDEN BROCHURE
R. E. Goldsmith* (CA), A. K. C. Chan, W. M. Seroski, L. Wizowski

PP-WE-432 AN EXPLORATION OF THE LIVED EXPERIENCES OF PATIENTS LIVING WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA
V. Ragoonanan* (UK)

PP-WE-433 INFLUENCE OF PUBLIC AWARENESS ABOUT DVT SYMPTOMS AND BURDEN ON THE RATE OF CONFIRMED DVT EVENTS
W. Z. Tomkowski* (PL), P. Andziak, M. Dybowska, A. Jawien, P. Kuca, K. Ziaja, G. Malek, M. Gorska

PP-WE-434 SELF ADMINISTRATION OF C1-INHIBITOR-CONCENTRATE IN PATIENTS WITH HEREDITARY ANGIODEMA (HAE)
W. Kreuz* (DE), E. Rusicke, I. Martinez-Saguer, C. Heller, E. Aygören-Pürsün, T. Klingebiel

PP-WE-435 ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND ARTERIAL ISCHEMIC STROKE IN CHILDREN
D. Coen Herak* (HR), M. Milos, J. Lenicek Krleza, R. Zrinski Topic, S. Dodig, V. Duranovic, R. Zadro

PP-WE-436 D-DIMER CONCENTRATIONS IN UMBILICAL CORD BLOOD OF NORMAL NEONATES
E. Grau* (ES), P. Correcher, J. Tenias, R. Garcia, M. Santos, E. Monteagudo, F. Calvo

PP-WE-437 DO BOLUS DOSES OF UFH CONTRIBUTE TO INCREASED BLEEDING RISKS IN CHILDREN
F. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, P. Monagle

PP-WE-438 UNFRACTIONATED HEPARIN HAS AN AGE-DEPENDENT PHARMACOKINETIC PROFILE IN CHILDREN
F. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, R. Summerhayes, N. Cranswick, P. Monagle

PP-WE-439 THE ROLE OF THROMBIN GENERATION IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
H. Bernhard* (AT), A. Deutschmann, B. Leschnik, M. Novak, A. Hauer, H. Haidl, A. Rosenkranz, W. Muntean

PP-WE-440 PRESUMED PERINATAL ISCHAEMIC STROKE
H. Platokouki* (GR), H. Pergantou, A. Komitopoulou, P. Xafaki, S. Aronis

PP-WE-441 TREATMENT OF DEEP VEIN THROMBOSIS WITH CONTINUOUS INTRAVENOUS INFUSION OF LMWH IN CHILDREN – AN UPDATE
J. Blatny* (CZ), V. Fiamoli

PP-WE-442 HEREDITARY THROMBOPHILIA AND HYPOFIBRINOLYSIS IN A FAMILY WITH MULTIPLE PROTHROMBOTIC RISK FACTORS - A CASE REPORT
J. Lenicek Krleza* (HR), G. Jakovljevic, D. Coen Herak, A. Bronic, R. Zadro, M. Nakic

PP-WE-443 CEREBRAL SINUS VENOUS THROMBOSIS IN PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA: A SINGLE CENTRE EXPERIENCE
J. D. Robertson* (AU), C. Ryan, D. Castle, S. Williams, L. Brandao

PP-WE-444 EVALUATION OF VON WILLEBRAND FACTOR AND ADAMTS13 IN CHILDREN WITH ALL DURING INDUCTION THERAPY
J. D. A. Carneiro* (BR), E. A. D’Amico, T. R. F. Rocha, C. S. S. S. Silva, V. Odone-Filho, D. A. F. Chamone

PP-WE-445 SYSTEMATIC LITERATURE REVIEW OF ILIAC VEIN COMPRESSION SYNDROME IN PEDIATRIC PATIENTS
B. H. L. Tam, A. K. Chan, S. Williams, L. Brandao* (CA)

PP-WE-446 ADVERSE OUTCOMES FOLLOWING NON-CEREBRAL ARTERIAL THROMBOSES IN NEONATES: A CASE-SERIES REPORT
J. Franco, S. Williams, G. Chaudry, B. Connonly, D. Castle, L. R. Brandao* (CA)

PP-WE-447 THE IMPACT OF PROPHYLACTIC CRYOPRECIPITATE AND FRESH FROZEN PLASMA ON THE INCIDENCE OF CNS THROMBOSES IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) RECEIVING ASPARAGINASE
V. Price, L. S. Abbott* (CA), M. Deveeska, D. R. Barnard, C. V. Fernandez, M. Yhap, C. Fitzgerald, D. Dix, J. N. Berman

PP-WE-448 COMPARISON OF HEMOCLOT TO STANDARD COAGULATION ASSAYS FOR MONITORING THE DIRECT THROMBIN INHIBITOR (DABIGATRAN) IN PEDIATRIC PATIENTS: AN IN VITRO STUDY
L. G. Mitchell* (CA), K. Dietrich, L. Stang, W. Etches, S. Qayyum

PP-WE-449 LACK OF ASSOCIATION OF PROTHROMBIN 20112A, FACTOR V LEIDEN, LP(A) OR VIII:C WITH THROMBOSIS IN CHILDREN UNDERGOING SURGERY FOR CORRECTION OF CONGENITAL HEART DISEASE
L. G. Mitchell* (CA), K. Dietrich, I. Rebeyka, D. Ross, S. Qayyum

PP-WE-450 THE EFFECT OF THE TOPICAL ANAESTHETIC MAXILENE ON ENOXAPARIN METABOLISM AS MEASURED BY PEAK ANTI-Xa LEVELS
M. E. Bauman* (CA), S. Duncan, L. Ray, L. Bajzar, S. Kuhle, M. P. Massicotte

PP-WE-451 DEVELOPMENT AND VALIDATION OF A COMPLEMENTARY ALTERNATIVE MEDICINE EDUCATIONAL HANDOUT AND PERFORMANCE EVALUATION TOOL FOR ANTICOAGULATED CHILDREN
M. E. Bauman* (CA), G. Mack, A. Bruce, K. L. Black, M. P. Massicotte

PP-WE-452 ADMINISTRATION OF ANTITHROMBIN CONCENTRATE AND EFFECT ON ANTICOAGULATION
M. E. Bauman* (CA), M. L. Bauman, K. L. Black, L. Bajzar, M. P. Massicotte

PP-WE-453 MANAGEMENT OF SUBCUTANEOUS PROTEIN C SUBSTITUTION IN CHILDREN WITH SEVERE PROTEIN C DEFICIENCY
M. Olivieri* (DE), C. Bidlingmaier, W. Behnisch, I. Engelsberger, A. Kienast, A. Krümpel, U. Nowak-Göttl, M. Sigl-Kraetzig, K. Kurnik

PP-WE-454 POOLED ANALYSIS OF TWO RANDOMIZED STUDIES COMPARING FONDAPARINUX 2.5MG AND ENOXAPARIN 40MG FOR PREVENTING VENOUS THROMBOEMBOLISM (VTE) IN HIP SURGERY USING NEW STUDY ENDPOINTS
M. R. Lassen* (DK)

PP-WE-455 THROMBOTIC RISK IN THALASSEMIC PATIENTS
N. Dhouib, N. Ben Romdhane* (TN), F. Mallouli, S. Mahjoub, H. Kallel, R. Ellouze, M. Bejaoui

PP-WE-456 STUDY OF INHERITED AND ACQUIRED PROTHROMBOTIC RISK FACTORS IN PEDIATRIC PATIENTS WITH THROMBOSIS
J. Ahluwalia, S. Naseem* (IN), R. Das, P. Singhi, B. Thapa, S. Singh, N. Varma

PP-WE-457 INCIDENCE OF PTS AFTER INDIVIDUALLY TAILORED DURATION OF ELASTIC COMPRESSION THERAPY
A. J. ten Cate-Hoek* (NL), H. ten Cate, J. Tordoir, K. Hamulyák, M. H. Prins

PP-WE-458 VENOUS THROMBOSIS RISK FACTORS ARE ASSOCIATED WITH RISK OF VENOUS INSUFFICIENCY
M. Cushman* (US), P. W. Callas, M. H. Criqui, J. O. Denenberg, E. G. Bovill

PP-WE-459 FREQUENCY OF HEREDITARY THROMBOPHILIC RISK FACTORS IN IRANIAN PATIENTS WITH DEEP VEIN THROMBOSIS
M. Karimi* (IR), M. Yavarian, M. Ramzi, M. Zakernia, M. Dehgani, A. Afrasiabi, H. Nourani Khojaste

PP-WE-460 THROMBOPHILIA DOES NOT INCREASE THE RISK OF THE POST-THROMBOTIC SYNDROME. A PROSPECTIVE COHORT STUDY
L. Spiezia, E. Campello, E. Giolo, D. Tormene, P. Simioni, S. Villalta, P. Prandoni* (IT)

PP-WE-461 MEASUREMENT PROPERTIES OF THE VILLALTA SCALE TO DEFINE AND CLASSIFY THE SEVERITY OF THE POST-THROMBOTIC SYNDROME
S. R. Kahn* (CA)

PP-WE-462 FEASIBILITY OF RECRUITMENT AND RETENTION IN AN UNBLINDED RANDOMIZED CONTROLLED TRIAL OF EXERCISE TRAINING FOR THE POST-THROMBOTIC SYNDROME
S. R. Kahn* (CA), A. Houweling, S. Shapiro, A. Muladzanov, I. Shrier, A. M. Hirsch, R. Reid, C. Kearon, M. A. Rodger, M. J. Kovacs, D. Anderson, P. S. Wells

PP-WE-463 INCREASED CALF MUSCLE DEOXYGENATION DURING LIGHT-INTENSITY EXERCISE SUGGESTS INCREASED VENOUS REFLUX FLOW IN ADVANCED HUMAN CHRONIC VENOUS DISEASE
T. Yamaki* (JP), M. Nozaki, H. Sakurai, K. Soejima, A. Hamahata, K. Kim

PP-WE-464 USE OF WARFARIN AND DRUGS WITH POTENTIAL INTERACTION IN A HEALTH MAINTENANCE ORGANIZATION (HMO) FROM CÓRDOBA, ARGENTINA
A. H. Tabares* (AR), A. I. Casanegra

PP-WE-465 APPROPRIATE VTE PROPHYLAXIS, COMPARED WITH PARTIAL VTE PROPHYLAXIS, LEADS TO LOWER VTE RECURRENCE AND COST IN US MEDICAL PATIENTS
A. N. Amin* (US), M. Hussein, D. Battleman, J. Lin, S. Stemkowski, G. J. Merli

PP-WE-466 REAL-WORLD EFFECTIVENESS OF ANTITHROMBOTIC AGENTS FOR INTPATIENT TREATMENT OF VENOUS THROMBOEMBOLISM
A. F. Shorr* (US), M. M. Bonafede, B. H. Johnson, R. V. Horblyuk

PP-WE-467 CHARACTERISTICS OF HOSPITAL ADMISSIONS FROM A LARGE NATIONWIDE SAMPLE OF PULMONARY EMBOLISM PATIENTS IN THE UNITED STATES: PREVALENCE, OUTCOME, AND CHARGES
D. M. Courtney* (US), R. K. Khare

PP-WE-468 APPARENT OVERUTILIZATION OF THROMBOPHILIA SCREENING PANELS: AN ANALYSIS OF PHYSICIAN ORDERING PATTERNS AT AN URBAN ACADEMIC MEDICAL
K. P. Patel, J. Somma, H. Rose, I. I. Sussman, J. H. Rand* (US)

PP-WE-469 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150MG IN CANADA FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL KNEE OR HIP ARTHROPLASTY THAT HAVE MODERATE IMPAIRMENT OF RENAL FUNCTION
C. Bradley-Kennedy, S. E. Wolowacz, N. S. Roskell, A. Clemens, J. M. Plumb* (DE)

PP-WE-470 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE IN CANADA FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP REPLACEMENT SURGERY
C. Bradley-Kennedy, S. E. Wolowacz, N. S. Roskell, J. M. Plumb* (DE)

PP-WE-471 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE IN CANADA FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS UNDERGOING TOTAL KNEE REPLACEMENT SURGERY (TKR)
C. Bradley-Kennedy, S. E. Wolowacz, N. S. Roskell, J. M. Plumb* (DE)

PP-WE-472 ECONOMIC COMPARISON OF RIVAROXABAN WITH ENOXAPARIN IN THE UK AND SWEDEN
L. Ryttberg* (SE), I. Bjorholt, A. Diamantopoulos, L. Gilmour, M. Lees

PP-WE-473 COST-EFFECTIVENESS OF RIVAROXABAN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL HIP OR KNEE REPLACEMENT (THR, TKR) IN THE US
L. Kwong* (US), A. Duran, A. Diamantopoulos, N. Sengupta, M. Lees

PP-WE-474 EVALUATION OF CLOTTING TESTS USING A NEW HIGH THROUGHPUT HEMOSTASIS ANALYZER
M. McInerney* (IE), N. Kelly, E. Kearney, J. Landowska, J. Grace

PP-WE-475 THE QUALITY OF ANTICOAGULANT THERAPY IN THE INITIAL TREATMENT PERIOD OF PATIENTS WITH PULMONARY EMBOLISM
M. J. Agterof* (NL), E. R. van Bladel, B. Frijling, R. van der Griend, M. H. Prins, R. E. G. Schutgens, D. H. Biesma

PP-WE-476 PERFORMANCE OF A PORTABLE MONITOR OF PROTHROMBIN TIME IN A UNIVERSITY ANTICOAGULATION CLINIC IN BRAZIL
M. M. Fiusa, M. S. Pereira* (BR), E. V. de Paula, F. A. Orsi, S. Custodio, J. M. Annichino-Bizzacchi

PP-WE-477 THROMBOPROPHYLAXIS WITH DALTEPARIN IN BARIATRIC SURGERY: A RETROSPECTIVE CHART REVIEW OF 2,138 PATIENTS
M. Snyder* (US)

PP-WE-478 IMPACT OF VENOUS THROMBOEMOLISM IN US MEDICARE PATIENTS UNDERGOING TOTAL HIP AND TOTAL KNEE REPLACEMENT SURGERY
O. Baser* (US), D. Supina, N. Sengupta, L. Wang, L. M. Kwong

PP-WE-479 RENAL DYSFUNCTION IN OLDER PATIENTS IS ASSOCIATED WITH REDUCED WARFARIN MAINTENANCE DOSE AND DECREASED ANTIOCOAGULATION STABILITY
P. Whittaker* (US), C. L. Garwood, M. E. Kleinow, K. Curtis, J. L. Clemente

PP-WE-480 DEVELOPMENTAL DIFFERENCES IN PROCOAGULANT PHOSHOLIPID/MICROPARTICLE CONCENTRATION
R. Summerhayes* (AU), V. Ignjatovic, P. Monagle

PP-WE-481 AVE5026: A NEW HEMISYNTHETIC ULTRA LOW MOLECULAR WEIGHT HEPARIN WITH ENRICHED ANTI-Xa ACTIVITY AND ENHANCED ANTITHROMBOTIC ACTIVITY FOR MANAGEMENT OF CANCER ASSOCIATED THROMBOSIS
A. Gray* (US), D. Hoppensteadt, W. Jeske, J. M. Walenga, J. Fareed

PP-WE-482 UPREGULATION OF PROCALCITONIN IN CANCER PATIENTS WITH VENOUS THROMBOSIS
D. Hoppensteadt* (US), O. Iqbal, C. Adiguzel, J. Cunanan, J. Fareed

PP-WE-483 STANDARDS, OPTIONS : RECOMMENDATIONS 2008 THROMBOEMBOLIC EVENTS TREATMENT IN CANCER PATIENTS
D. Farge Bancel* (FR), L. Bosquet, P. Mismetti, I. Mahe, F. Cajfinger, H. Desmurs Clavel, G. Meyer, C. Grange, H. Hocini, J. Renaudin, H. Levesque, P. Debourdeau

PP-WE-484 PROTEIN C PATHWAY VALUES, HOMOCYSTEINE AND ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOPROLIFERATIVE DISORDERS
E. Papadakis* (GR), S. Efraimidou, K. Loukidhs, K. Kokoviadou, M. Speletas, I. Korantzis, M. Sion

PP-WE-485 ROLE OF TISSUE FACTOR (TF) IN LEUKEMIA-ASSOCIATED COAGULATION ACTIVATION AND VEGF EXPRESSION
B. Spath, A. Amirkhosravi, J. L. Francis, C. Bokemeyer, B. Eifrig, F. Langer* (DE)

PP-WE-486 INCREASED ACQUIRED ACTIVATED PROTEIN C RESISTANCE IN UNSELECTED PATIENTS WITH HEMATOLOGIC MALIGNANCIES
H. F. S. Negaard* (NO), P. O. Iversen, B. Østenstad, M. Mowinckel, P. M. Sandset

PP-WE-487 REGULATORS OF EXTRACELLULAR MATRIX TURNOVER ARE NOT STRONGLY CORRELATED WITH HEMOSTATIC PARAMETERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
H. F. S. Negaard* (NO), K. Svennevig, S. O. Kolset, P. O. Iversen, B. Østenstad, N. Iversen, P. M. Sandset

PP-WE-488 SUCCESSFUL THERAPY OF AN EXTENSIVE VENA CAVA SUPERIOR THROMBOSIS WITH INTRAVENOUS LOW MOLECULAR WEIGHT HEPARIN (DALTEPARIN)
H. Schinzel* (DE), S. Schadmand-Fischer, T. Achenbach, D. Peetz, K. Fruth

PP-WE-489 APIXABAN IN PATIENTS WITH METASTATIC CANCER: A RANDOMIZED PHASE II FEASIBILITY STUDY
H. Liebman* (US), M. N. Levine, D. Deitchman, J. Julian, C. P. Escalante, M. C. O’Brien, L. M. Ramirez, L. Weise-Kelly, S. Solymoss

PP-WE-490 ALTERATION OF THE LMWHS INHIBITORY EFFECT ON THROMBIN GENERATION BY DIFFERENT HISTOLOGICAL TYPES OF CANCER CELLS. AN IN VITRO STUDY
V. Galea, M. Mbemba, A. Khaterchi, C. Prengel, J. Bernaudin, M. Hatmi, I. Elalamy* (FR), G. T. Gerotziafas

PP-WE-491 PROTEIN C, THROMBOMODULIN AND ENDOTHELIAL PROTEIN C RECEPTOR IN ACUTE MYELOBLASTIC LEUKAEMIA
M. Galar, J. Sokolowski, K. Mazgajska-Barczyk, J. Kloczko* (PL)

PP-WE-492 PROTEIN Z IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
J. Oleksiuk, E. Luksza, J. Kloczko* (PL), M. Galar

PP-WE-493 PROCOAGULANT PROPERTIES OF CANCER CELLS
J. C. Bordet* (FR), K. Villaume, J. Y. Scoazec, C. Negrier

PP-WE-494 THE ROLE OF SOLUBLE FIBRIN IN LYMPHOCYTE AND LAK CELL ADHERENCE TO AND DIAPEDESIS ACROSS ENDOTHELIAL CELLS: IMPLICATIONS FOR IMMUNOTHERAPY AND CANCER
J. P. Biggerstaff* (US), B. L. Weidow

PP-WE-495 HYPERCOAGULATION IN MALIGNANCY LOCALIZED BY THROMBOELASTOGRAPHY TO THE HUMORAL PHASE OF COAGULATION
K. A. Schwartz* (US), S. Nagpal, E. A. Faber, D. Estrada, D. Schwartz, A. Cziffer, C. Puttarajappa

PP-WE-496 VENOUS THROMBOEMBOLISM IN GASTRIC CANCER: INCIDENCE AND CLINICAL CHARACTERISTICS
K. Lee* (KR), S. Bang, Y. Kim, J. Kim, H. Kim, D. Park, J. Lee

PP-WE-497 MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY, VENOUS THROMBOEMBOLISM AND POOR SURVIVAL IN PANCREATIC CANCER PATIENTS
M. E. T. Tesselaar* (NL), F. Romijn, P. Garcia-Rodrigues, I. van der Linden, R. Bertina, S. Osanto

PP-WE-498 THROMBOTIC COMPLICATIONS IN ADULT PATIENTS WITH LYMPHOMA: A METAANALYSIS
V. Caruso, A. di Castelnuovo, V. C. Lein, G. de Gaetano, M. A. Lazzari, S. Storti, L. Iacoviello, M. B. Donati* (IT)

PP-WE-499 JAK2 V617F ALLELE BURDEN AND HEMOSTATIC PROFILE OF ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS
M. Marchetti* (IT), E. Castoldi, L. Russo, A. Vignoli, J. Rosing, H. ten Cate, A. Falanga

PP-WE-500 EVALUATING RISK FOR RECURRENT VENOUS THROMBOEMBOLISM (VTE) ACCORDING TO MALIGNANCY CHARACTERISTICS IN PATIENTS WITH CANCERASSOCIATED-THROMBOSIS: A SYSTEMATIC REVIEW OF OBSERVATIONAL AND INTERVENTION STUDIES
M. L. Louzada* (CA), H. H. M. Majeed, V. V. D. Dao, P. P. W. Wells

PP-WE-501 ACTIVATION OF COAGULATION BY ANTINEOPLASTIC DRUGS FOR MULTIPLE MYELOMA
M. Nishio* (JP), A. Hoshi, J. Chung, A. Matsumoto, T. Koyama

PP-WE-502 EPOPROSTENOL INHIBITS TISSUE FACTOR EXPRESSION IN HUMAN CANCER AND TUMOR-ASSOCIATED HOST CELLS
A. Cutrone, E. Napoleone, G. Colavecchia, W. Zamboni, G. de Gaetano, M. B. Donati, R. Lorenzet* (IT)

PP-WE-503 INCIDENTAL SPLANCHNIC THROMBOSIS IN CANCER PATIENTS
S. M. Ramasamy* (UK), G. Bozas, G. Avery, A. Maraveyas

PP-WE-504 VENOUS THROMBOEMBOLISM (VTE) RISK STRATIFICATION IN HOSPITALIZED CANCER PATIENTS |
S. B. Hijjawi* (JO), S. G. Jallad, B. A. Ababneh, H. N. Abdel-Razeq

PP-WE-505 PLASMA SOLUBLE FIBRIN LEVEL, A CLINICALLY USEFUL PREDICTOR OF THROMBOSIS IN CANCER PATIENTS
S. Mirshahi* (FR), C. Soria, J. Chidiac, R. Varin, K. Khalfi, E. Pujade-Lauraine, M. Mirshahi, B. J. Woodhams, J. Soria

PP-WE-506 DEVELOPMENT OF A NOVEL HEPARANASE ACTIVITY ASSAY AND IDENTIFICATION OF POTENT HEPARANASE INHIBITORS
S. Alban* (DE), S. Schiemann

PP-WE-507 PRODUCTION OF VWF MAY MEDIATE LYMPHOBLAST INDUCED THROMBIN ACTIVATION IN CHILDREN WITH NEWLY DIAGNOSED ALL
U. Athale* (CA), A. Moghrabi, T. Nayiger, D. Yves-Line, L. Thabane, A. Chan

PP-WE-508 IS COCKADE DEEP VEIN THROMBOSIS OF THE LOWER LIMBS ASSOCIATED WITH AN INCREASED FIBRINOLYTIC POTENTIAL
A. Delluc* (FR), A. Rousseau, P. Quehe, G. Le Gal, K. Lacut, E. Oger, P. vanDreden, D. Mottier, L. Bressollette

PP-WE-509 D-DIMER (DD) LEVELS AT DIAGNOSIS IN RELATION TO THE SITE AND EXTENSION OF LEG DEEP VEIN THROMBOSIS (DVT)
C. Legnani* (IT), M. Cini, K. Cavallaroni, G. Rodorigo, S. Cavazza, L. Valdrè, A. Amato, G. Palareti

PP-WE-510 VALIDITY OF ANGULAR SUM AS PLANAR EXTRACTION TECHNIQUE OF LUNG VENTILATION-PERFUSION SPECT DATA
P. Cambefort, A. Le Duc-Pennec, P. Guillo, F. Couturaud, S. Querellou, R. Abgral, G. Le Gal* (FR), D. Mottier, C. Leroyer, P. Salaun

PP-WE-511 ILEO-FEMORAL THROMBOSIS IN A PATIENT WITH ELEVATED HOMOCYSTEINE DUE TO THREE POLYMORPHISMS IN THE MTHFR GENE
H. A. Guglielmone* (AR), S. Minoldo, G. Jarchum

PP-WE-512 SAFETY OF RULING OUT ACUTE PULMONARY EMBOLISM BY NEGATIVE CT PULMONARY ANGIOGRAPHY IN PATIENTS WITH A STRICT INDICATION FOR CT: SYSTEMATIC REVIEW AND META-ANALYSIS
I. C. M. Mos* (NL), F. A. Klok, L. J. M. Kroft, A. de Roos, O. M. Dekkers, M. V. Huisman

PP-WE-513 CONTRAST INDUCED NEPHROPATHY FOLLOWING CT-PULMONARY ANGIOGRAPHY FOR CLINICALLY SUSPECTED PULMONARY EMBOLISM
J. Kooiman* (NL), F. A. Klok, I. C. M. Mos, J. T. Tamsma, Y. W. J. Sijpkens, M. V. Huisman

PP-WE-514 CLINICAL EVALUATION OF NEW QUANTITATIVE D-DIMER ASSAYS FOR EXCLUSION OF DEEP VEIN THROMBOSIS
J. L. Elf* (SE), K. Strandberg, P. J. Svensson

PP-WE-515 DIAGNOSTIC PERFORMANCE OF AQT90 FLEX D-DIMER IN PATIENTS SUSPECTED FOR DEEP VENOUS THROMBOSIS - COMPARISON WITH FOUR WELL-ESTABLISHED D-DIMER TESTS
J. J. Sidelmann* (DK), J. Gram, J. Jespersen

PP-WE-516 DEEP VENOUS THROMBOEMBOLISM IN A PATIENT OF FACTOR V DEFICIENCY
K. Nishiya* (JP), K. Nogami, Y. Kikukawa, K. Shinozawa, H. Yada, K. Fukutake, M. Shima

PP-WE-517 PROTEIN C AND S LEVELS CAN BE ACCURATELY MEASURED DURING AN ACUTE VENOUS THROMBOEMBOLISM (VTE)
L. Minuk, A. Lazo-Langner* (CA), M. Kovacs

PP-WE-518 FREQUENCY OF FACTOR V LEIDEN AND PROTHROMBIM 20210A AS THROMBOTIC AND GENETIC RISK FACTORS FOR PREECLAMPSIA IN THE SOUTH IRANIAN PROVINCE
M. Yavarian* (IR), S. Karimi, L. Ahmadian, M. Karimi

PP-WE-519 EVALUATION OF PRECISION, ACCURACY AND SUITABILITY OF EDTA PLASMA FOR A NEW ROCHE D-DIMER ASSAY
A. Busse Grawitz, M. Mueller, G. Honauer, H. Maier, M. Wilmer* (CH), A. Hubbuch

PP-WE-520 FIBRIN MONOMER: DOES IT HELP IMPROVE THE SENSITIVITY AND SPECIFICITY OF THE D-DIMER ASSAY FOR IDENTIFICATION OF VENOUS THROMBOEMBOLISM
M. Johnston* (CA), E. Ali, N. McEwen, S. Bates

PP-WE-521 HIGH PERCENTAGE OF NON-DIAGNOSTIC COMPRESSION ULTRASONOGRAPHY RESULTS IN THE DIAGNOSIS OF IPSILATERAL RECURRENT DEEP VEIN THROMBOSIS
M. Tan* (NL), S. I. Velthuis, C. J. van Rooden, R. E. Westerbeek, M. V. Huisman

PP-WE-522 THE UTILITY AND FEASIBILITY OF SCREENING FOR DEEP VENOUS THROMBOSIS IN PRIMARY CARE PRACTICE
M. D. Creagh* (UK), P. Carson, S. Herbert, M. Kazi, A. McSorley

PP-WE-523 FACTORS WHICH INFLUENCE PRIMARY CARE PHYSICIANS WHEN REFERRING PATIENTS TO A HOSPITAL OUTPATIENT DVT SCREENING SERVICE
M. D. Creagh* (UK), H. Bond, S. Gupta, A. McSorley

PP-WE-524 CEREBRAL VENOUS THROMBOSIS RISK FACTORS AND INCIDENCE OF JAK2 V617F MUTATION
M. Kotál* (CZ), P. Dulíek, J. Mal, D. Krajíková

PP-WE-525 PERFORMANCE OF A NEW TURBIDIMETRIC D-DIMER ASSAY ADAPTED TO AUTOMATED COAGULOMETERS
B. Arza, T. Sánchez, L. Del Toro, M. Sales* (ES), J. Arnout

PP-WE-526 PROLONGATION OF ENOXAPARIN THERAPY TO ONE MONTH ACCELERATES RECANALIZATION OF DEEP VEIN THROMBOSIS
N. M. Vorobyeva* (RU), E. P. Panchenko, A. B. Dobrovolsky, A. I. Kirienko, T. V. Balakhonova

PP-WE-527 THE VALUE OF 64-DETECTOR ROW COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF PULMONARY EMBOLISM
R. Pesavento, G. de Conti, I. Minotto, F. Maurizi, M. Mongiat, A. Pagnan, P. Prandoni* (IT)

PP-WE-528 MALE PREDOMINANCE IN CHILDHOOD STROKE AND VENOUS THROMBOEMBOLISM REVISITED:
U. Nowak-Gottl* (DE), S. Normann, M. Fobker, C. Langer, R. Strater, G. Deveber

PP-WE-529 BONE MINERAL DENSITY IN HEMOPHILIA PATIENTS: A META-ANALYSIS
M. Marcucci, G. Fabbriciani, M. Brozzetti, A. Iorio* (IT)

PP-WE-530 FUNCTIONAL LIMITATIONS IN HEMOPHILIA A: COMPARISON OF A SELFASSESSMENT TOOL AND JOINT ROM
A. Zakarija* (US), J. Brewer, S. Harris, D. Green

PP-WE-531 THROMBIN GENERATION AND FIBRINOLYSIS PARAMETERS IN BOYS WITH SEVERE HAEMOPHILIA A
A. Greenway* (AU), V. Ignjatovic, R. Summerhayes, C. Barnes, J. Furmedge, J. Ekert, P. Monagle

PP-WE-532 DETECTION OF LARGE REARRANGEMENTS BY MLPA IN SEVERE HEMOPHILIA A PATIENTS
N. Lannoy, I. Abinet, C. Lambert* (BE), C. Vermylen, K. Dahan, C. Hermans

PP-WE-533 UNUSUAL INTRON 1 INVERSION WITH CONCOMITANT LARGE DUPLICATION WITHIN THE F8 GENE IN A SEVERE HEMOPHILIA A PATIENT
M. Badoz, D. Pellechia, M. Fretigny, V. Roussel-Robert, N. Stieltjes, C. Negrier, C. Vinciguerra* (FR)

PP-WE-534 EVALUATING THERAPY IN HEMOPHILIA: DEVELOPMENT OF AN MRI PROTOCOL
I. E. M. den Uijl* (NL), A. M. A. de Schepper, D. E. Grobbee, K. Fischer

PP-WE-535 PROSPECTIVE EVALUATION OF SAFETY AND EFICAY OF RADIOSYNOVIORTHESIS WITH HYDROXYAPATITE-YTTRIUM IN CHRONIC SYNOVITIS IN HEMOPHILIA: PRELIMINARY RESULTS
J. B. J. Silva* (BR), J. M. Annichino-Bizzacchi, R. G. Pagnano, H. Hong, M. A. P. Matta, A. L. A. Sambo, R. G. Roveri, E. Bortoletto, J. Mengatti, C. D. Ramos, A. O. Santos, M. C. Ozelo, E. V. de Paula

PP-WE-536 ANALYSIS OF INTRON 1 AND INTRON 22 INVERSION IN FACTOR VIII GENE IN PATIENTS WITH HAEMOPHILIA A
J. Wu* (CN), T. Li, J. Dai, Q. Ding, X. Wang, K. Ding, C. Zheng

PP-WE-537 THE RELATIVE BURDEN OF HEMOPHILIA ON HEALTH RELATED QUALITY OF LIFE
J. D. Epstein* (US), J. M. Li-McLeod, A. S. Yarlas, G. C. Hammond

PP-WE-538 THE IMPACT OF TARGET JOINT DEVELOPMENT ON HEALTH RELATED QUALITY OF LIFE FOR ADULT HEMOPHILIA A PATIENTS: RESULTS FROM THE PASS STUDY
J. D. Epstein* (US), J. M. Li-McLeod, A. S. Yarlas

PP-WE-539 INCIDENCE OF PORT INFECTIONS IN A COHORT OF BOYS WITH HAEMOPHILIA – IMPACT OF RIGOROUS ANTISEPTIC TECHNIQUE TRAINING IN THE HOME
J. Mitchell* (UK), D. Bevan, S. Rangarajan, B. Sørensen

PP-WE-540 HIGHER CD4+CD25HIGH TREG CELLS IN HAEMOPHILIA PATIENTS WITH FVIII INHIBITOR
K. Ding* (CN), J. Wu, T. Li, Y. Sheng

PP-WE-541 LONG-TERM BLEEDING HISTORY AS A TOOL FOR HEMOPHILIA MANAGEMENT
K. L. Strike, A. K. C. Chan, T. M. Almonte, K. P. Decker* (CA), R. E. Goldsmith Rn, I. Walker, M. J. Wright

PP-WE-542 RESOURCE CONSUMPTION IN HAEMOPHILIA CARE - THE ESCHQOL STUDY (EUROPEAN STUDY OF CLINICAL, HEALTH ECONOMIC AND QUALITY OF LIFE OUTCOMES IN HAEMOPHILIA TREATMENT
K. Berger* (DE), M. Bullinger, P. Giangrande, A. Giebl, A. Gringeri, R. Ljung, L. Nemes, S. von Mackensen, L. Mantovani, M. Serban, M. Shlaen, W. Schramm

PP-WE-543 SKEW RATIOS OF FEMALE HEMOPHILIA PATIENTS IN KOREA
K. Y. Yoo* (KR), S. Kwon, M. Lee

PP-WE-544 GENETIC MUTATIONS IN MILD HAEMOPHILIA A FAMILIES IN SOUTH AUSTRALIA
L. H. Tay* (AU), S. Rodgers, S. McRae, Z. Rudzki, E. Duncan, J. Lloyd

PP-WE-545 SEVERE HEMOPHILIA B DUE TO AN APPROXIMATELY 100 KB FACTOR IX GENE DELETION INVOLVING THREE DISTAL EXONS
L. Kokabee* (IR), N. Karimi, S. Zeinali, M. Karimipoor

PP-WE-546 HYPERMOBILITY AND ARTHROPATHY IN HEMOPHILIA: A RETROSPECTIVE EVALUATION OF JOINT HYPERMOBILITY AS A RISK FACTOR FOR ARTHROPATHY IN SEVERE AND MODERATE HEMOPHILIA
L. A. Skeith* (CA), S. C. Jackson, J. Brooks, M. Poon

PP-WE-547 HAEMOPHILIA A PATIENTS WITH DISCORDANT FVIII LEVELS BY 1-STAGE & CHROMOGENIC ASSAYS SHOW REDUCED THROMBIN GENERATION & INCREASED BLEEDING
L. T. Khoo* (AU), G. W. Kershaw, J. Curnow, M. Morel-Kopp, S. Matthews, C. Waite, S. Dunkley

PP-WE-548 THE INVERSE ASSOCIATION BETWEEN HEMOPHILIA AND CARDIOVASCULAR MORTALITY IS NOT EXPLAINED BY DIFFERENCES IN CARDIOVASCULAR RISK PROFILE
M. A. Baarslag* (NL), S. Rafi, M. J. H. A. Kruip, M. Peters, P. W. Kamphuisen

PP-WE-549 LOCOMOTOR STATUS – CLINICAL EXPRESSION OF THE QUALITY OF CARE IN HEMOPHILIA - MULTICENTRIC STUDY
M. Serban* (RO), L. Pop, L. Ritli, P. Stancu, H. Ionita, D. Mihailov, D. Baghiu, A. Cucuianu, V. Uscatescu, E. Ursu, A. Lacatusu, L. Barna, D. Poenaru, W. Schramm

PP-WE-550 INTEGRAL ASSESSMENT OF FEMALE HEMOPHILIA CARRIERS
M. E. Mingot* (ES), A. Palomo, A. Heiniger

PP-WE-551 HEMOPHILIAC PATIENT SERUM BANK: EVALUATION OF THE INFLUENCE OF EMERGING PATHOGENS AND INFECTIOUS RISKS ASSOCIATED TO REPLACEMENT THERAPY AFTER TWO YEARS FOLLOW-UP
M. E. Mingot* (ES), M. García, J. A. Fernández, A. Palomo, A. Heiniger, J. Camacho

PP-WE-552 HAEMOPHILIA ACTIVITIES LIST-USEFUL INSTRUMENT IN SELF-ASSESSMENT OF MUSCULOSKELETAL FUNCTION IN ROMANIAN HEMOPHILIACS
M. Mihailov* (RO), L. Pop, R. Ladislau, G. Miculschi, C. Jinca, D. Lighezan, A. Lacatusu, E. Ursu, W. Schramm, M. Serban

PP-WE-553 RISK FACTORS OF BLEEDING SEVERITY IN YOUNG BOYS WITH SEVERE HEMOPHILIA A ON TAILORED PROPHYLAXIS: LONG-TERM (10-YEAR) RESULTS FROM THE CANADIAN HEMOPHILIA PRIMARY PROPHYLAXIS STUDY
M. X. Hang* (CA), V. S. Blanchette, E. Pullenayegum, P. Babyn, R. Card, A. Chan, C. Demers, K. Gill, S. Israels, R. Klaassen, N. Laferriere, D. Lillicrap, K. Luke, M. McLimont, M. Pai, M. Poon, V. Price, G. E. Rivard, S. Robinson, M. Steele, J. K. M. Wu, B. Feldman

PP-WE-554 HEMOPHILIA A AND CARDIOVASCULAR EVENTS: A CASE SERIES
M. Zwiers* (NL), W. M. Lijfering, K. Meijer, J. D. Lefrandt, A. J. Smit, J. van der Meer

PP-WE-555 DIFFERENTIATION OF PATIENTS WITH SEVERE HEMOPHILIA A BY FACTOR VIII ACTIVITY: A MASS SPECTROMETRY APPROACH
M. van Geffen* (NL), B. Verbruggen, M. E. Mancuso, B. Laros-Vangorkom, E. Santagostino, W. L. van Heerde

PP-WE-556 THE DIFFERENTIAL PREDICTIVE VALUE OF THROMBIN GENERATION IN HAEMOPHILIA A AND B DEPENDANT ON TISSUE FACTOR
M. W. Besser* (UK), R. Luddington, T. Baglin

PP-WE-557 A THROMBIN GENERATION TEST IN FVIII-DEFICIENT MOUSE PLASMA
M. Dockal* (AT), R. Hartmann, M. Fries, E. Panholzer, A. Schiviz, E. M. Muchitsch, F. Scheiflinger

PP-WE-558 CARRIER DETECTION USING THREE POLYMORPHIC DNA MARKERS IN HEMOPHILIA A FAMILIES FROM MAZANDARAN, NORTHERN PROVINCE OF IRAN
M. Hashemi Soteh* (IR), Z. Hosseini Khah, M. Bagherian, R. Mohseni, E. Siami, F. Vali Zadeh, R. Zaki Zadeh

PP-WE-559 AFIBRINOGENAEMIA; AN IRANIAN EXPERIENCE
M. R. Baghaipour* (IR)

PP-WE-560 HAEMOPHILIA A IN FEMALE PATIENTS
M. Martin-Salces* (ES), M. Alvarez, I. Fernandez, N. Butta, I. Muñoz, M. Garcia, I. Rivas, V. Jimenez, F. Hernandez

PP-WE-561 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN RUSSIA: PATIENT-REPORTED DATA
P. A. Vorobyev, O. V. Borisenko, U. A. Zhulev, K. G. Kopylov, E. A. Telnova, A. A. Tonoyan, N. I.